Donnelly et al: Immuno-metabolic Signatures of Depressive Symptoms

1 Title Page

2 Article Type: Research Report

3

- 4 Title
- 5 Blood Immuno-metabolic Biomarker Signatures of Depression and Affective
- 6 Symptoms in Young Adults

7

8 Authors

- 9 Nicholas A Donnelly^{1,2,3} MRCPsych, PhD (corresponding author,
- 10 <u>nick.donnelly@bristol.ac.uk</u>)
- 11 Ruby SM Tsang^{1,2}, PhD
- 12 Éimear M Foley^{1,2}, PhD
- 13 Holly Fraser^{1.2}, PhD
- 14 Aimee L Hanson¹, PhD
- 15 Golam M Khandaker^{1,2,3,4} FRCPsych, PhD
- 16
- 17 Affiliations
- 18 ¹MRC Integrative Epidemiology Unit, Bristol Medical School, University of Bristol,
- 19 Bristol, UK
- 20 ²Centre for Academic Mental Health, Population Health Sciences, Bristol Medical
- 21 School, University of Bristol, Bristol, UK

Donnelly et al: Immuno-metabolic Signatures of Depressive Symptoms

- ³Avon and Wiltshire Mental Health Partnership NHS Trust, Bristol, UK
- ⁴NIHR Bristol Biomedical Research Centre, University Hospitals Bristol and Weston
- 24 NHS Foundation Trust, Bristol, UK
- 25
- 26 Running Title
- 27 Immuno-metabolic Signatures of Depressive Symptoms
- 28

29 Keywords

- 30 Depressive disorders
- Anxiety
- Inflammation
- Metabolic Dysregulation
- Machine learning
- 35 ALSPAC

Donnelly et al: Immuno-metabolic Signatures of Depressive Symptoms

36 Highlights

37	٠	Immuno-metabolic biomarkers show varying, opposing associations with
38		somatic, mood and anxiety symptoms.
39	•	Depression diagnosis and fatigue are associated with increased extreme-
40		valued inflammatory markers.
41	•	Two latent components (somatic-inflamed vs anxious-non-inflamed) represent
42		the relationship between biomarkers, symptoms and key covariates.
43	٠	Higher somatic-inflamed scores are associated with greater depressive
44		symptom severity in follow-up.
45	•	Immuno-metabolic biomarkers predict depression and depression with high
46		somatic symptoms, but not high anxiety symptoms, better than chance.

Donnelly et al: Immuno-metabolic Signatures of Depressive Symptoms

47 Abstract

48 Background

- 49 Depression is associated with alterations in immuno-metabolic biomarkers, but it
- 50 remains unclear whether these alterations are limited to specific markers, and
- 51 whether there are subtypes of depression and depressive symptoms which are
- 52 associated with specific patterns of immuno-metabolic dysfunction.

53 Methods

- 54 To investigate whether immuno-metabolic biomarkers could be used to profile
- subtypes of depression, we applied regression, clustering, and machine learning to a

56 dataset comprising depression diagnosis, depressive and anxiety symptoms, and

- 57 blood-based immunological and metabolic biomarkers (n=118). We measured
- 58 inflammatory proteins, cell count, lipids, hormones, and metabolites from up to
- 59 n=4161 participants (2363 female, 337 with depression) aged 24 years from the
- 60 Avon Longitudinal Study of Parents and Children birth cohort.

61 Results

- 62 Depression at age 24 was associated with both altered concentrations of immuno-
- 63 metabolic markers, and increased extreme-valued inflammatory markers.
- 64 Inflammatory and metabolic biomarkers show distinct, opposing associations with
- 65 somatic and anxiety symptoms. We identified two latent components representing
- 66 the relationship between blood biomarkers, symptoms, and covariates, one
- 67 characterised by higher somatic symptoms and inflammatory markers (neutrophils,
- 68 WBC, IL-6), and the other characterised by higher anxiety and worry and lower
- 69 inflammatory markers (CRP, WBC, IL-6). Individuals with higher somatic-
- 70 inflammatory component scores had greater depressive symptoms severity over the

Donnelly et al: Immuno-metabolic Signatures of Depressive Symptoms

- 71 next five years. Immuno-metabolic biomarkers predicted depression diagnosis
- 72 (Balanced Accuracy=0.580) and depression with high somatic symptoms (Balanced
- 73 Accuracy=0.575) better than chance, but not depression with high anxiety symptoms
- 74 (Balanced Accuracy=0.479).

75 Conclusions

- 76 Alterations in immuno-metabolic homeostasis is present in young adults with
- 77 depression well before the typical age of onset of cardiometabolic diseases. The
- 78 relationships between affective symptoms and blood immunometabolic biomarkers
- 79 indicate two biotypes of depressive symptoms (somatic-inflamed vs anxious-non-
- 80 inflamed). These patterns are relevant for prognosis and prediction, highlighting the
- 81 potential usefulness of immuno-metabolic biomarkers for depression subtyping.

Donnelly et al: Immuno-metabolic Signatures of Depressive Symptoms

82 1. Introduction

The presence of immunological and metabolic alterations in depression has been
widely replicated, including changes in the concentrations of blood inflammatory
biomarkers (e.g., cytokines, acute phase proteins and immune cell counts (Foley et
al., 2023; Frank et al., 2021; Goldsmith et al., 2016; Lynall et al., 2020; Osimo et al.,
2020)) and metabolic biomarkers (e.g., lipids and metabolites (Bot et al., 2020;
Davyson et al., 2023)).

89 Existing case-control studies have typically focused on specific biomarker domains 90 (e.g., proteins, metabolic biomarkers, cells). Studies involving broader sets of 91 biomarkers could clarify if immuno-metabolic alterations in depression are restricted 92 to a few biomarkers or reflect broader disruption of immuno-metabolic homeostasis. 93 Studies also typically compare mean biomarker levels between case and control 94 groups, and often overlook substantial individual variability in biomarkers, which can 95 provide important additional information regarding the overall pattern of change 96 (Osimo et al., 2020). Recent neuroimaging findings suggest that depression and 97 other psychiatric disorders are characterised by increased total number of extreme 98 deviations from normative models of grey matter volume (Segal et al., 2023), but it is 99 unclear whether such extreme variability is present in immuno-metabolic measures. 100 Depression is a syndrome comprising core symptoms of low mood and anhedonia, 101 alongside depressive cognitions (e.g., guilt and hopelessness), anxiety symptoms, 102 and somatic symptoms (e.g. fatigue, and changes to sleep and appetite). It is 103 possible that immuno-metabolic processes have differing relationships to different 104 symptoms (Milaneschi et al., 2021). Published symptom-level investigations have 105 involved few specific inflammatory markers, most often interleukin 6 (IL-6) and C-

Donnelly et al: Immuno-metabolic Signatures of Depressive Symptoms

106	reactive protein (CRP). These biomarkers appear to be particularly associated with
107	somatic, atypical or energy-related symptom domains which include increased sleep
108	increased weight, fatigue, anhedonia and reduced motivation (Chu et al., 2019;
109	Frank et al., 2021; Milaneschi et al., 2021), indicating that particular depression
110	symptom profiles could be associated with specific immuno-metabolic biomarker
111	patterns.

112 By examining the association between a broad set of immuno-metabolic biomarkers

and the spectrum of depressive presentations, from individual symptoms to symptom

114 domains and overall diagnosis, it may be possible to identify distinct clusters of

biomarker-symptoms associations. Such associations could infer biomarker-based

116 depression biotypes that might inform prognosis and treatment decisions, similar to

117 those proposed using brain imaging data (Tozzi et al., 2024).

118 We report an in-depth exploration of the relationship of blood immuno-metabolic

biomarkers (118 inflammatory proteins, cell count, lipids, and hormones) and

120 depression measures (ICD-10 depression diagnosis, 4 symptom domains and 22

121 symptoms) based on data from young adults aged 24 years from the Avon

122 Longitudinal Study of Parents and Children (Northstone et al., 2019), a UK birth

123 cohort. In particular, we aimed to: (1) examine the pattern of immuno-metabolic

biomarker associated with ICD-10 depression compared to controls, including

125 extreme values of biomarkers; (2) quantify relationships between individual

126 symptoms and immuno-metabolic variables, and explore if these associations

127 formed distinct clusters or latent components; and (3) investigate whether machine

128 learning models trained on immuno-metabolic variables can predict ICD-10

129 diagnoses of depression and specific symptom profiles within depression identified

- 130 using the symptom clustering approach, comparing model performance with models
- 131 trained on sociodemographic and clinical data.

Donnelly et al: Immuno-metabolic Signatures of Depressive Symptoms

132 2. Materials and Methods

- 133 2.1 Datasets
- 134 2.1.1 Cohort Profile
- 135 We used data from the Avon Longitudinal Study of Parents and Children (ALSPAC)
- birth cohort (Boyd et al., 2013; Fraser et al., 2013; Northstone et al., 2019). This
- 137 cohort study recruited pregnant women in the Avon region of England between 1990
- and 1992 (Golding et al., 2001). After all rounds of recruitment, the final number of
- people recruited as children in study who were alive at age 1 was 14,901.
- 140 Participants in the study have been followed up with regular clinical and
- 141 questionnaire-based assessments, and over 80,000 variables are available. Study
- 142 data are captured and managed using the REDCap tool, hosted at the University of
- 143 Bristol (Harris et al., 2019, 2009). Variables can be explored through a fully
- 144 searchable data dictionary (<u>http://www.bristol.ac.uk/alspac/researchers/our-data/</u>),
- 145 and data is available on a managed open access basis.
- 146 Ethical approval for the study was obtained from the ALSPAC Ethics and Law
- 147 Committee and Local Research Ethics Committees. All participants provided written
- 148 informed consent. Biological samples were collected with informed consent and in
- 149 accordance with the UK Human Tissue Act (2004).

150 2.1.2 Mental Health Data

- 151 Our main outcomes for our cross-sectional analysis were ICD-10 depression
- 152 diagnosis and specific symptoms and symptom domains derived from the Clinical
- 153 Interview Schedule Revised (CIS-R (Lewis et al., 1992)) and the Community
- 154 Assessment of Psychic Experiences (CAPE (Mossaheb et al., 2012)) questionnaires
- 155 at age 24.

156	Given previous research suggesting that depressive symptoms can be best
157	described by a "psychological" and a "somatic" factor (Thorp et al., 2020), we
158	derived a domain score for psychological (0-4 scale) and somatic (0-9 scale)
159	symptoms. For comparison to previous studies (Donnelly et al., 2022; Lamers et al.,
160	2020; Milaneschi et al., 2021) we also created atypical (0-5 scale) and anxiety (0-7
161	scale) symptom domain scores.
162	We derived individual depression symptoms, combining items from the CIS-R and
163	CAPE to target a wide set of symptoms, including those previously been associated
164	with inflammation and metabolic dysfunction. This produced a total of 22 individual
165	items: Aches & Pains (ach), Anhedonia (anh), Anxiety (anx), Appetite Decreased
166	(app_dec), Appetite Increased (app_inc), Concentration Impaired (con), Depressive
167	Cognitions – feelings of guilt, inadequacy and helplessness (dcog), Decreased
168	interested in sex (dsx), Fatigue (ftg), Irritability (irt), Morning low mood (morn),
169	Motivation impairment (mot), Panic (pan), Phobias/specific fears (pho), Restlessness
170	(rstl), Sadness/low mood (sad), Slowed movements (slow), Sleep Decreased
171	(slp_dec), Sleep Increased (slp_inc), Self-neglect (sneg), Suicidal Thoughts (stb),
172	and Worry (wor). Full details of score derivations including ALSPAC variable codes

- 173 used are given in the **Supplementary Methods**.
- 174 We used the Short Mood and Feeling Questionnaire (SMFQ (Rhew et al., 2010))
- total score, completed by ALSPAC participants at four timepoints between ages 25
- and 30, as outcomes in prospective longitudinal analysis.
- 177 2.1.3 Blood Biomarkers
- 178 As exposures we included a set of immune proteins measured by the Olink Target
- 179 96 Inflammation Panel (Goulding et al., 2022) alongside blood cell counts, lipids,

Donnelly et al: Immuno-metabolic Signatures of Depressive Symptoms

180	hormones and metabolites measured at age 24 (Supplementary Table 1). Blood
181	samples were taken during F24 clinic visits in lithium heparin tubes, which were
182	placed on ice immediately, spun down, plasma extracted and frozen at -80 $^{\circ}$ C within
183	90 minutes. A total of 3027 blood samples from the F24 clinic were processed by
184	Olink. The Olink Target 96 Inflammation panel detects a set 92 immune response-
185	related proteins, returning Olink Proteomics' arbitrary normalised protein expression
186	(NPX) values on a log_2 scale. Within the ALSPAC sample, a correlation of 0.77 has
187	been demonstrated between a clinical chemistry assay and the Olink measure of
188	Interleukin-6, indicating consistency between the measures (Goulding et al., 2022).
189	We combined the Olink data with blood test results from the original F24 clinic, giving
190	a total of 118 immuno-metabolic variables, based on having >90% complete data.
191	We included all Olink measures regardless of limit of detection as all measurements
192	may have biological relevance. For multiple imputation analysis we used Olink data
193	from 3005 individuals who had the same variables measured at age 9 (of whom
194	1826 had measurements at both age 9 and 24, see Supplementary Methods).

- 195 2.2 Statistical Analysis
- 196 2.2.1 Software

197 Statistical Analysis was carried out using R Statistical Software (version 4.4.2 (R

- 198 Development Core Team, 2017)).
- 199 22.2 Immuno-metabolic Variable Selection and Preparation
- 200 All Olink data were expressed as Normalised Protein Expression (NPX values) on a
- 201 log₂ scale, therefore, no further transformations were performed. Non-Olink blood
- 202 variables were log₂ transformed prior to analysis. All immuno-metabolic variables
- were z-transformed by subtracting the overall mean value and dividing by the

Donnelly et al: Immuno-metabolic Signatures of Depressive Symptoms

- standard deviation, such that a 1-unit change in model results represents a 1
- standard deviation (SD) unit change in the immuno-metabolic variable. Z-
- transformation was used to allow comparison between all immuno-metabolic
- 207 variables on the same scale, and for consistency of model fitting.
- 208 2.2.3 Univariate Statistical Models
- 209 We identified potential covariates using a directed acyclic graph ((Tennant et al.,
- 210 2021), **Supplementary Methods**): sex assigned at birth (reference group=male),
- 211 BMI at age 24, daily smoking (reference group=non-smoker), alcohol use (measured
- 212 via the AUDIT-C questionnaire) and self-reported physical health problems
- 213 (combining reported diabetes, asthma or COPD, arthritis, heart disease or heart
- 214 problems, stroke, cancer or kidney disease into a single binary variable indicating
- absence or presence). In line with ALSPAC guidance when tabulating covariates,
- cell counts of less than 5 are replaced with "<5".
- 217 For each immuno-metabolic variable, we fit two statistical models: (1) unadjusted
- 218 model: depression diagnosis as outcome and the immuno-metabolic variable as
- 219 predictor, (2) an adjusted model adding all covariates. Models were fit using the glm
- 220 function, and average marginal effects (AME) calculated using the marginal effects
- 221 package, where we calculated the average change in probability of depression with a
- 1 SD unit increase in the immuno-metabolic variable. We were interested in both
- 223 positive and negative changes in risk of depression. Given our large number of
- immuno-metabolic variables, we controlled the false discovery rate using the
- Bioconductor *swfdr* package (Boca and Leek, 2018; Korthauer et al., 2019).
- 226 As sensitivity analyses we investigated the impact of sex on the association between
- haemoglobin and depression by repeating our models stratified by sex at birth.

Donnelly et al: Immuno-metabolic Signatures of Depressive Symptoms

233	Supplementary Methods.
232	blood variables and CIS-R-derived outcomes were imputed. For full details, see
231	blood sample data processed by Olink at age 9 or age 24 (total $n = 4164$). All age 24
230	Random Forest method. MI was performed on data from participants who either had
229	to impute missing data in our age 24 dataset, using the R mice package and the
228	To investigate the impact of attrition from the cohort we used multiple imputation (MI)

234 2.2.3 Symptom-Biomarker Association

235 We fit models predicting depression measures (diagnosis, domain scores and 236 symptom scores) using immuno-metabolic variables and the full set of covariates 237 (above) for all pairs of depression- and immuno-metabolic measures. Models were fit 238 with a binomial distribution using *qlm*. We then took the matrix of AME values for all 239 pairs of symptoms and immuno-metabolic variables and applied the hclust function 240 in the R stats package, using Euclidean distance and the "complete" method. The 241 resulting dendrogram indicated that maximum separation between variables was 242 achieved by a 3-cluster solution. Clusters were manually labelled after inspecting 243 their constituent associations.

244 2.2.5 Extreme Value Analysis

245 We explored whether a given immuno-metabolic variable was extreme valued by 246 taking non-depressed participants and calculating a normative model for each 247 variable (using *Im* and our full set of covariates as predictors). Then, for each 248 participant (both non-depressed and depressed) a standardised residual was 249 calculated using the model fit to non-depressed individuals. A standardised residual 250 was classified as "extreme" if the absolute value was greater than 2.6, based on a 251 study applying a similar approach to brain imaging (Segal et al., 2023). We then took 252 the sum of extreme values across immuno-metabolic variables for each individual.

Donnelly et al: Immuno-metabolic Signatures of Depressive Symptoms

- 253 Models predicting the count of extreme values from depression diagnosis or
- 254 depression symptoms were fit with all covariates using a Poisson mixed effects
- 255 model with participant ID as a random intercept.

256 2.2.6 Partial Least Squares

- 257 We fit principal components analysis (PCA) and partial least squares models (PLS)
- to depressive symptom scores and biomarker variables (from the positive and
- 259 negative association clusters) using the mixOmics package. PLS was performed
- using the *spls* function (Rohart et al., 2017) in "regression" mode. All covariates were
- 261 included in PLS models. We selected 2 latent components for further analysis after
- applying a cross-validation approach, inspecting model performance with 1–5
- 263 components. A 2-component solution was optimal based on inspecting the Q2
- 264 statistic. We next used cross-validation to select the number of variables for each
- 265 component, selecting variables using the "cor" measure.
- 266 We extracted PLS component scores for all components and individuals and used
- the scores as predictors of the total sum score on subsequent SMFQ measurements
- aged 25 30, using a generalised linear mixed model with a poisson distribution, fit
- 269 with the *glmm* function in the lme4 package.
- 270 2.2.7 Machine Learning Model Fitting
- 271 We fit elastic net regression models with the glmnet R package to predict ICD-10
- 272 depression diagnosis. In addition, we assessed predictive performance of two
- 273 symptom profiles within participants with ICD-10 depression: depression with high
- levels of anxiety (high anxiety and worry, sum score \geq 5) or depression *with* high
- somatic symptoms (fatigue, decreased sleep, low motivation, and aches & pains;

Donnelly et al: Immuno-metabolic Signatures of Depressive Symptoms

sum score \geq 9). The cut-offs were chosen to produce balanced groups based on the

- 277 distributions of symptom profile scores.
- 278 We used four sets of predictors: (1) Immuno-metabolic: positive and negative-
- association cluster variables, plus extreme value counts and covariates; and three
- sets of comparison predictors: (2) Sociodemographic: all covariates, plus maternal
- 281 occupational social class and history of adverse childhood events aged 0–17
- 282 (Houtepen et al., 2018); (3) Mental Health History: previous CIS-R depression
- 283 diagnosis at age 18, SMFQ total score at ages 10 to 23, Strengths and Difficulties
- 284 (SDQ) Total Difficulties Score at ages 7 and 9, and Maternal Edinburgh Postnatal
- 285 Depression Scale Score; (4) *Full*: all variables included in previous models.
- 286 Nested cross-validation (20 outer folds, 20 inner folds) was used to tune model
- 287 hyperparameters (penalty and mixture parameters, see **Supplementary Methods**).
- 288 Model performance was measured using balanced accuracy (Sensitivity +
- 289 Specificity) / 2 to allow comparison to similar analyses (e.g. (Winter et al., 2024)),
- evaluated by fitting a model to the held-out test data on each outer fold, for all 20
- 291 outer loops and calculating the mean and 95% confidence interval of these
- 292 performance results.

Donnelly et al: Immuno-metabolic Signatures of Depressive Symptoms

293 3. Results

- 294 3.1 Cohort Profile
- 295 The complete case dataset contained 2954 individuals (Male N=1082, Female
- 296 N=1872), of whom 309 (10.5%) had ICD-10 depression at age 24 (Table 1 and
- 297 Supplementary Figure 1B-G).
- 298 Table 1
- 299 Table 1: Characteristics of ALSPAC study sample
- 300

Variable	Overall	Sex at Birth		
	$N = 2,954^{1}$	Male	Female	
		N = 1,082 ¹	N = 1,872 ¹	
ICD-10 Depression				
No Depression	2,645 (90%)	1,011 (93%)	1,634 (87%)	
Depression	309 (10%)	71 (6.6%)	238 (13%)	
BMI @ 24	23.6 (21.4, 26.8)	24.1 [21.8, 26.8]	23.3 [21.3, 26.8]	
Missing	28	6	22	
Daily Smoking @ 24	341 (12%)	130 (12%)	211 (11%)	
Missing	18	7	11	
AUDIT Alcohol Questionnaire Score @ 24	5.00 (4.00, 7.00)	6.00 [4.00, 8.00]	5.00 [3.00, 7.00]	
Missing	32	13	19	

Donnelly et al: Immuno-metabolic Signatures of Depressive Symptoms

Self-reported physical health conditions	379 (13%)	148 (14%)	231 (13%)
Missing	85	30	55
Self-reported health by type			
Arthritis	16 (0.6%)	5 (0.5%)	11 (0.6%)
Asthma or COPD	320 (11%)	125 (12%)	195 (11%)
Diabetes	(0.5%)	(0.9%)	-
Heart Disease or Heart problems	23 (0.8%)	6 (0.6%)	17 (0.9%)
Kidney Disease	<5	<5	<5
Stroke or cancer	<5	<5	<5
Missing	85	30	55
' n (%); Median [Q1, Q3] note cell counts w	vith n < 5 are replac	ed with "<5" or not	shown in line
with ALSPAC guidance.			

Donnelly et al: Immuno-metabolic Signatures of Depressive Symptoms

302 3.2 Biomarker-Depression Associations

- 303 We examined the associated between immuno-metabolic variable levels (n=118
- 304 immuno-metabolic variables) and risk of depression. The results represent the
- 305 change in probability of depression associated with a 1 standard deviation unit
- 306 change in the immuno-metabolic variable of interest, where a positive value indicates
- 307 an increase in risk, and a negative value indicates a decrease in risk.
- 308 In unadjusted analysis, after correction for multiple comparisons, 11 blood measures
- 309 were associated with depression (Table 2): Haematocrit (average marginal effect
- 310 [95% confidence interval]) = -0.022 [-0.033, -0.011], Haemoglobin = -0.019 [-0.03, -
- 311 0.008], Aspartate aminotransferase (AST) = -0.018 [-0.031, -0.005], Red blood cell
- 312 count =-0.018 [-0.029, -0.007], Alanine aminotransferase (ALT) = -0.017 [-0.029, -
- 313 0.005]), Platelets = 0.016 [0.006, 0.027], Insulin = 0.018 [0.007, 0.029], CUB domain-
- 314 containing protein 1 (CDCP1) = 0.019 [0.009, 0.029], White blood cell (WBC) count =
- 315 0.021 [0.011, 0.031], Interleukin-6 (IL-6) = 0.021 [0.012, 0.031] and Neutrophil count
- 316 = 0.022 [0.012, 0.032].
- 317 Evidence for association remained for ALT, IL-6, and neutrophil count after
- 318 adjustment for covariates (sex at birth, smoking, alcohol use, BMI and physical
- 319 health conditions), though the respective P-Values did not survive correction for
- 320 multiple testing. See **Supplementary Table 1** for results for all biomarkers.

Donnelly et al: Immuno-metabolic Signatures of Depressive Symptoms

321 Table 2

322 Table 2: Immuno-metabolic biomarker associations with ICD-10 depression at

323 age 24 years in the ALSPAC cohort

Immuno-metabolic Variable	Unadjusted	Adjusted
Alanine aminotransferase (ALT)	-0.017 [-0.029, -0.005]	-0.015 [-0.028, -0.002]
Aspartate aminotransferase (AST)	-0.018 [-0.031, -0.005]	-0.01 [-0.024, 0.003]
CUB domain-containing protein 1 (CDCP1)	0.019 [0.009, 0.029]	0.011 [-0.001, 0.022]
Haemoglobin (Hb)	-0.019 [-0.03, -0.008]	-0.003 [-0.018, 0.013]
Haematocrit (Hct)	-0.022 [-0.033, -0.011]	-0.011 [-0.025, 0.003]
Interleukin-6 (IL-6)	0.021 [0.012, 0.031]	0.016 [0.004, 0.027]
Insulin	0.018 [0.007, 0.029]	0.007 [-0.006, 0.02]
Neutrophils	0.022 [0.012, 0.032]	0.013 [0.002, 0.024]
Platelets	0.016 [0.006, 0.027]	0.009 [-0.003, 0.021]
Red blood cell count (RBC)	-0.018 [-0.029, -0.007]	-0.006 [-0.022, 0.01]

Donnelly et al: Immuno-metabolic Signatures of Depressive Symptoms

	White blood cell count (WBC)	0.021 [0.011, 0.031]	0.01 [-0.001, 0.021]
324			

325 Footnote: Biomarkers were selected based on FDR-corrected P-Value (P_{FDR}) of

326 <0.05 in the unadjusted model. Values displayed are Average Marginal Effects (95%

327 Confidence Interval); positive values indicate higher absolute risk of depression

328 associated with a 1 standard deviation unit increase in that immuno-metabolic

329 variable; negative values indicate a lower absolute risk of depression associated with

a 1 standard deviation unit increase. See Supplementary Table 1 for results for all

331 biomarkers.

332

We carried out a series of sensitivity analyses. To investigate the impact of missing data due to cohort attrition we used multiple imputation for missing data and fit the same models to the imputed data. The results showed similar patterns of association (**Supplementary Figure 2**).

337 The observed association between haemoglobin and depression was explained by

338 sex at birth. On average males had haemoglobin values 17.6 g/L higher than

females, while females had a 5.87% higher rate of depression than males. There

340 was no association between depression and haemoglobin when modelling stratified

341 by sex; for males the average marginal effect of a 1 SD unit change in Hb was -

342 0.001 [-0.017, 0.015] and for females -0.002 [-0.017, 0.014].

343 We adjusted our univariate models for self-reported physical health conditions. As

344 some conditions were rare (e.g. diabetes), we were unable to test associations

- 345 between individual conditions and depression. However, the overall prevalence of
- 346 self-reported physical health conditions was not higher in participants with
- 347 depression (12.1%) than in participants without (13.3%), Chi-Squared test X_{df=1}=
- 348 0.268, P-Value = 0.604.

Donnelly et al: Immuno-metabolic Signatures of Depressive Symptoms

349 3.3 Symptom-Biomarker Association Clusters

- 350 We carried out exploratory analyses to investigate whether immuno-metabolic
- 351 variables were associated with individual depression and anxiety symptoms (n=22)
- and symptom domains (n=4, **Supplementary Methods and Supplementary Figure**
- 353 **3)**, and whether immuno-metabolic variables could be clustered on these
- 354 associations.
- 355 We found differing patterns of associations between immuno-metabolic variables

and symptoms (Figure 1), with some immuno-metabolic biomarkers appearing to

- 357 have positive associations with most symptoms (e.g. CCL25), whereas others
- 358 appeared to have largely negative associations (e.g. ALT). Somatic or atypical

359 symptoms or symptom domains as well as psychological symptoms had positive

- 360 associations with many immuno-metabolic variables (i.e. higher levels of biomarkers
- 361 were associated with *higher* probability of endorsing a symptom), whereas in general
- 362 anxiety and worry had negative associations (i.e. higher levels of biomarkers were
- 363 associated with *lower* probability of endorsing a symptom).
- 364 Hierarchical clustering applied to all pairwise associations of symptoms and immuno-
- 365 metabolic variables identified three clusters, which were distinct with regards to their
- 366 relationship to symptoms (see **Supplementary Table 1** for the cluster identity of all
- 367 immuno-metabolic variables). Cluster 1 (*negative association*) comprised 24
- 368 immuno-metabolic variables, including some immune cell counts (lymphocytes,
- basophils), liver enzymes (ALT, AST and γ GT), metabolic markers (Triglycerides,
- 370 VLDL) and markers of red blood cell function (Hct, Hb, RBC), alongside cytokines
- 371 that showed negative associations with symptoms, particularly anxiety and worry.
- 372 Cluster 3 (*positive association*) comprised 21 biomarkers which included cytokines
- 373 (e.g., IL6), chemokines (e.g., CCL4 and CCL25) immune cell counts (e.g.,

- neutrophils, monocytes and white blood cells) and growth factors (FGF19, FGF21,
- 375 HGF, GDNF). Variables in this cluster showed positive associations with specific
- 376 somatic and psychological symptoms (including depressive cognitions, impaired
- 377 motivation, fatigue, and decreased sleep). Cluster 2 (*low association*) comprised 73
- 378 biomarkers with predominantly small associations with symptoms.

Donnelly et al: Immuno-metabolic Signatures of Depressive Symptoms

379 Figure 1



Donnelly et al: Immuno-metabolic Signatures of Depressive Symptoms

381 Figure 1: Associations of immuno-metabolic variables with depression and

382 anxiety-related measures in the ALSPAC cohort

- 383 Matrix plots showing the average marginal effect of a 1 SD-unit change in an
- immuno-metabolic variable on the probability of endorsing a symptom. From top to
- 385 bottom, plots are of 22 individual depressive/anxiety symptom scores: Aches & Pains
- 386 (ach), Anhedonia (anh), Anxiety (anx), Appetite Decreased (app_dec), Appetite
- 387 Increased (app_inc), Concentration Impaired (con), Depressive Cognitions feelings
- 388 of guilt, inadequacy and helplessness (dcog), Decreased interested in sex (dsx),
- 389 Fatigue (ftg), Irritability (irt), Morning low mood (morn), Motivation impairment (mot),
- 390 Panic (pan), Phobias/specific fears (pho), Restlessness (rstl), Sadness/low mood
- 391 (sad), Slowed movements (slow), Sleep Decreased (slp_dec), Sleep Increased
- 392 (slp_inc), Self-neglect (sneg), Suicidal Thoughts (stb) and Worry (wor) (see
- 393 **Supplementary Methods** for derivations); four depressive/anxiety symptom domain
- 394 scores (anxiety, atypical, psychological and somatic) and ICD-10 depression
- 395 diagnosis. Within each plot, marginal histograms represent the averaged marginal
- 396 effect over all rows for each column in the plot (i.e., average over all outcomes to
- 397 give an overall effect for each immuno-metabolic variable), marginal histograms to
- 398 the right represent the averaged AME over all columns for each row in the plot (i.e.
- 399 average over all immuno-metabolic variables for each outcome). At the top, the
- 400 dendrogram from hierarchical clustering of the CIS-R symptom score matrix;
- 401 immuno-metabolic variables are grouped based clustering of all mental health
- 402 measures. Symptoms are also sorted by a similar clustering process. Note that all
- 403 matrix plots are on the same colour scale. Coloured bars at the top indicate the
- 404 cluster identity assigned to each immuno-metabolic variable: red = positive
- 405 association; grey = low association; blue = negative association.

Donnelly et al: Immuno-metabolic Signatures of Depressive Symptoms

406

407 3.4 Extreme Valued Biomarkers in Depression

408	We carried out an	exploratory	analysis to	test if depress	sion diagnosis	was associated

- 409 with increases in the variability of immuno-metabolic markers, which could be
- 410 indicative of systemic immune or metabolic dysfunction. We calculated the total
- 411 number of extreme-valued measurements for each immuno-metabolic variable and
- 412 each participant.
- 413 All biomarkers had at least one participant with an extreme value; positive-signed
- 414 extreme values were more common than negative-signed values (Figure 2A). After
- 415 adjusting for covariates, participants with depression had higher total extreme-valued

416 biomarkers (on average participants without depression had 1.96 [1.90, 2.01]

- 417 extreme values, participants with depression had 2.25 [2.08, 2.43]; average
- 418 difference between groups in number of extreme values = 0.248 [0.056, 0.440],
- 419 **Figure 2B-C**).
- 420 Next, to test if extreme variability in biomarker level in depression is specific to any
- 421 biomarker cluster, we fit a model including immuno-metabolic cluster identity. We

422 found an interaction between depression and cluster on the number of extreme

423 values ($\chi^2_{df=2}$ =11.262, P=0.003). The number of extreme-valued biomarkers was

424 higher in people with depression for biomarkers belonging to the positive association

425 cluster (cluster 3; AME=0.104 [0.033, 0.174]), but not the other two clusters (AME for

- 426 the negative association cluster 1 = -0.015 [-0.070, 0.040], and AME for low
- 427 association cluster 2 = 0.067 [-0.085, 0.218]) (**Figure 2D**).

428 Finally, we fit models using scores on our symptom scales as predictors of number

429 of extreme variables (Figure 2E, Supplementary Table 2). After correction for

- 430 multiple comparisons, higher scores on the fatigue symptom scale (ftg) were
- 431 associated with higher extreme immuno-metabolic variables: a 1 unit increase in ftg
- 432 was associated with an average 0.089 (0.036, 0.142) increase in extreme values,
- 433 $P_{FDR} = 0.021$.

Donnelly et al: Immuno-metabolic Signatures of Depressive Symptoms

434 Figure 2





436 Figure 2: Extreme Value Distributions

- 437 A. Count of total number of positive (red) and negative (blue) valued immuno-
- 438 metabolic variables for each immuno-metabolic variables (refer to
- 439 **Supplementary Table 1** for full immuno-metabolic variable definition)
- 440 B. Histogram of proportion of participants with different counts of extreme values,
- 441 split by ICD-10 depression diagnosis.
- 442 C. Model-predicted average counts of extreme values per participant, split by
- 443 ICD-10 depression diagnosis, with 95% confidence interval
- 444 D. Model-predicted mean number of extreme values across immuno-metabolic
- 445 variables, grouped by clusters identified in **Figure 1**, with 95% confidence
- 446 *intervals.*
- 447 E. Model predicted association between symptom score and extreme value
- 448 count: average change in extreme value count associated with a 1 unit
- 449 increase in the focal symptom score, with 95% confidence intervals.
- 450 Symptoms as defined in **Figure 1**.
- 451

Donnelly et al: Immuno-metabolic Signatures of Depressive Symptoms

452 3.5 Latent Components Underlying Symptom - Immuno-metabolic Biomarker

- 453 Associations
- 454 Our clustering analysis identified that some immuno-metabolic variables had similar
- 455 profiles of association with depression and anxiety symptoms, and conversely some
- 456 symptoms had similar profiles of association with immuno-metabolic variables. We
- 457 explored corelations within immuno-metabolic variables. Immuno-metabolic variables
- 458 were generally positively correlated (Supplementary Figure 4A and C), with the
- 459 average correlation between variables being 0.114, SD = 0.1248. Principal
- 460 components analysis PCA) indicated one large principal component (PC) explained
- 461 16.7% of variance in immuno-metabolic variables, while 8 PCs together explained
- 462 50% of variance.
- 463 Applying the same analysis to individual depressive symptoms (Supplementary

464 **Figure 4B and D**), we found symptoms were also highly correlated (average

- 465 correlation = 0.235, SD = 0.144). PCA indicated one large component explained
- 466 54% of variance.
- 467 We used Partial Least Squares (PLS) regression to ask if there were latent variables
- 468 that capture covariation between immuno-metabolic biomarkers and depression
- symptoms. We fit a PLS model predicting 22 symptoms from the combination of 25
- 470 depression symptom-associated positive and negative association cluster
- 471 biomarkers we identified using our clustering analysis and our 5 covariates (sex at
- birth, BMI at age 24, daily smoking, AUDIT-C score, and self-reported physical
- 473 health conditions).
- 474 The best fitting PLS model identified 2 latent components explaining 22.1% of
- 475 variance in immuno-metabolic variables and 48.5% of variance in the depression

476	variables. Component 1 (labelled "Somatic-Inflamed") loaded on multiple somatic
477	and depressive symptoms (the top 4 variables by loading being fatigue, decreased
478	sleep, decreased motivation, and aches & pains); on the immuno-metabolic side this
479	component loaded most highly on higher neutrophil count, WBC count, IL-6 levels as
480	well as female sex, daily smoking, and higher BMI. By contrast, Component 2
481	(labelled "Anxiety-Non-inflamed") loaded on higher worry and anxiety, and lower
482	Adenosine Deaminase, Monocyte Chemotactic Protein 1 (MCP1), IL-6 and CRP
483	levels (Figure 3A-D).
484	Higher scores on both Components 1 and 2 were longitudinally associated with
485	higher SMFQ depressive symptoms score at follow-up between ages 25 and 30
486	(Figure 3E-F). On average, a 1 SD unit increase in Component 1 score at age 24
487	was associated with a 1.170 [0.969, 1.380]) unit increase in SMFQ score at age 25,
487 488	was associated with a 1.170 [0.969, 1.380]) unit increase in SMFQ score at age 25, declining to a 0.656 [0.471, 0.841] unit increase around age 30. For component 2, a

- 489 1 SD unit increase in score at age 24 was associated with a 0.401 [0.195, 0.607] unit
- 490 increase in SMFQ score, and a 0.298 [0.115, 0.480] unit increase around age 30.

Donnelly et al: Immuno-metabolic Signatures of Depressive Symptoms

491 Figure 3





494 immuno-metabolic variables and depressive symptoms

- 495 A: PLS Component 1 Loadings on symptoms.
- 496 B: As (A): Component 2 Loadings on symptoms
- 497 C: PLS Component 1 Loadings on immuno-metabolic variables

- 498 D: As (C): Component 2 Loadings on immuno-metabolic variables
- 499 E: Plot of Marginal change in SMFQ total score associated with a 1 SD unit increase
- 500 in PLS Component 1 score, with 95% confidence intervals, from generalised linear
- 501 *mixed model.*
- 502 F: As (F), marginal change in SMFQ total score for 1 unit increase in Component 2
- 503 score

Donnelly et al: Immuno-metabolic Signatures of Depressive Symptoms

504 3.6 Prediction of Depression and Specific Symptom Profiles using Immuno-

505 metabolic Biomarkers

- 506 Finally, we tested how well the immuno-metabolic variables we identified as being
- 507 associated with depression symptoms predict ICD-10 depression, using elastic net
- 508 regression. Informed by our symptom-based analyses which suggested a distinction
- 509 between somatic and mood symptoms vs anxiety symptoms, we also asked if
- 510 immuno-metabolic variables were better at predicting specific symptom types within
- 511 ICD-10 depression: depression *with* high levels of anxiety (high anxiety and worry;
- 512 n=197/337) or depression *with* high somatic symptoms (fatigue, decreased sleep,
- 513 low motivation and aches & pains; n=158/337), **Supplementary Figure 5**).
- 514 After nested cross-validation, models based on immuno-metabolic variables
- 515 performed better than chance in predicting ICD-10 depression diagnosis (Balanced
- 516 Accuracy=0.580; 95% CI = [0.568, 0.593]); Figure 4, Supplementary Table 3.
- 517 Performance was similar for models trained using socio-demographic factors (0.572
- 518 [0.560, 0.585]), while a model trained with past mental health history (0.710 [0.697,
- 519 0.722]) and a model containing all variables (0.708 [0.696, 0.721]) performed better.
- 520 Within ICD-10 depression, immuno-metabolic biomarkers could be used to provide
- 521 above-chance level predictions only of depression *with* high somatic symptoms
- 522 (0.575 [0.551, 0.599]) whereas immuno-metabolic variables were not predictive of
- 523 depression *with* high anxiety symptoms (0.479 [0.461, 0.498]). The difference in
- 524 balanced accuracy for immuno-metabolic variables predicting high somatic and
- 525 anxiety symptoms was 0.096 [0.066, 0.126]. By contrast, mental health history was
- 526 predictive of higher levels of both anxiety and somatic symptoms within individuals
- 527 with depression (**Supplementary Table 3**).

Donnelly et al: Immuno-metabolic Signatures of Depressive Symptoms

528 Figure 4





- 530 Figure 4: Performance of Machine Learning models predicting ICD-10
- 531 depression diagnosis and specific symptom profiles within individuals with
- 532 ICD-10 depression

- 533 Classification performance (balanced accuracy) of models trained with selected
- 534 immuno-metabolic variables predicting the presence of ICD-10 depression, high
- 535 anxiety symptoms within ICD-10 depression, or high somatic symptoms within ICD-
- 536 10 depression, with 95% confidence intervals

Donnelly et al: Immuno-metabolic Signatures of Depressive Symptoms

537 4. Discussion

538	This study provides several insights into the associations between peripheral blood
539	immune and metabolic biomarkers and depression symptoms. We found multiple
540	biomarkers to be associated with a higher probability of depression in young adults
541	as well as greater extreme variability in inflammatory biomarkers. The relationship
542	between biomarkers and depression symptoms varied, with clusters of biomarkers
543	showing distinct and opposing associations with somatic versus anxiety symptoms.
544	We identified two latent components potentially linking immuno-metabolic
545	biomarkers and depression symptoms, one somatic-inflammatory component
546	correlated with somatic symptoms, female sex, smoking and higher levels of
547	systemic inflammatory measures, while the anxious-non-inflamed component related
548	to anxiety, worry, female sex and lower levels of inflammatory biomarkers and
549	growth factors. Higher somatic-inflamed component scores were associated with
550	higher depressive symptoms severity in subsequent follow-up.
551	Machine learning models trained on immuno-metabolic biomarkers predicted ICD-10
552	depression diagnosis and depression with higher somatic symptoms, but not anxiety
553	symptoms, better than chance. Predictive performance was similar to models trained
554	on sociodemographic data, and to brain-imaging models (Winter et al., 2024).
555	However, performance was at an absolute level considered poor (Alba et al., 2017).
556	Unlike most previous studies (Chu et al., 2019; Davyson et al., 2023; Milaneschi et
557	al., 2021; Osimo et al., 2020), we examined a large number and variety of immuno-
558	metabolic biomarkers (118 in total) including inflammatory proteins, cell count, lipids,
559	and metabolites, which helped us identify key depression-related biomarkers (e.g.,

Donnelly et al: Immuno-metabolic Signatures of Depressive Symptoms

560 IL-6 and neutrophil count), reinforcing previous findings (Foley et al., 2023;

561 Milaneschi et al., 2021; Osimo et al., 2020).

562 In addition, we leverage our larger set of immuno-metabolic variables to show that

563 depression is associated more extreme valued biomarkers, as is the symptom

564 fatigue, consistent with a system-wide disruption in immuno-metabolic homeostasis

in young adults at age 24, and with a more somatic profile of symptoms. These

566 differences were not related to current physical health conditions and occur well

567 before the typical age of onset of cardiometabolic diseases, suggesting they are not

568 purely a result of the presence of other conditions.

569 CRP has been associated with depression in meta-analysis (Osimo et al., 2020), but

570 we did not reproduce this finding. There are several possible explanations for this

571 apparent discrepancy. Mendelian randomisation studies have suggested a potential

572 causal role of IL-6 in depression more consistently than CRP (Kappelmann et al.,

573 2021; Perry et al., 2021b). CRP has also been found to have a small or protective

574 effect against some mental disorders (Said et al 2022, Shi & Morrison 2025).

575 Longitudinal analysis of CRP has also suggested that there are specific trajectories

576 of raised CRP across childhood which are predictive of mental disorders (Palmer et

577 al., 2024). Therefore, although CRP is an archetypal clinical measure of systemic

578 inflammation, single cross-sectional measurements may not be as strongly

associated with depression as either upstream cytokines (e.g., IL-6), or longitudinaltrends.

581 Some lymphocytes, including CD4⁺ helper T cells, CD19⁺ B Cells and NK Cells,

have been found to be increased in depression (Foley et al., 2023). We did not find

an association between lymphocyte count, or CD244, the NK cell receptor, and

Donnelly et al: Immuno-metabolic Signatures of Depressive Symptoms

584	depression. However, CD244 is expressed on many immune cell types (Agresta et
585	al., 2018). Our null finding could be due to limited resolution of measures used (WBC
586	differential count) rather than flow-cytometry based subtyping.
587	We found several liver enzymes to be negatively associated with depression and
588	anxiety symptoms. This is in contrast to a previous study which have found
589	increased ALT in adults with higher depression scores (Zelber-Sagi et al., 2013). Our
590	study population differs to the previous study, being substantially less male and
591	much younger, meaning lower cumulative exposure to confounders such as alcohol.
592	We also observed a positive correlation between liver enzymes, IL-6 and markers of
593	red blood cell function. Lower Hb could be associated with poor health through
594	multiple mechanism including chronic disease, poor dietary iron intake, blood loss
595	and deficiencies in multiple vitamins (e.g. B12 and folate); therefore, lower liver
596	enzymes could be a correlate of these markers of poor health and lower Hb, which
597	also appeared to be associated with anxiety symptoms.
598	We also identified several novel potential biomarkers associated with depressive
599	symptoms including CCL25, FGF19 and FGF21. Expressed in the gut, CCL25 has
600	been associated with bipolar disorder (Göteson et al., 2022; Poletti et al., 2021),
601	post-traumatic stress disorder (Zhang et al., 2020), bowel inflammation (Wurbel et
602	al., 2011) and impaired intestinal barrier function (Jensen et al., 2023) in
603	schizophrenia. FGF19 and FGF21 are linked to glucose and glycogen metabolism
604	(BonDurant and Potthoff, 2018; Kir et al., 2011); FGF21 is associated with the risk of
605	type-two diabetes (Post et al., 2023).

Taken together, our findings suggest that there may be distinct immuno-metabolic
biotypes linked to specific symptom patterns in depression (somatic *vs* anxiety

Donnelly et al: Immuno-metabolic Signatures of Depressive Symptoms

608	symptoms). These putative biotypes could potentially map on to other hypothecated
609	depression biotypes, such as those based on brain imaging (Tozzi et al., 2024).
610	By assaying immuno-metabolic biomarkers, in combination with clinical history
611	(Arribas et al., 2025; Zhang et al., 2024), brain imaging (Fu et al., 2024) or
612	actigraphy (Price et al., 2025), patients could be stratified to give better information
613	on prognosis or targeting specific treatments. For example, an important question for
614	future research is whether patients with a somatic-inflammatory biotype could
615	improve more with anti-inflammatory drugs compared to patients with an anxious-
616	non-inflamed biotype.
- · -	
617	Given the association we identified between somatic symptoms and FGF19 and
617 618	Given the association we identified between somatic symptoms and FGF19 and FGF21, and these hormones and the effects of GLP-1 receptor agonists (Shao and
617 618 619	Given the association we identified between somatic symptoms and FGF19 and FGF21, and these hormones and the effects of GLP-1 receptor agonists (Shao and Jin, 2022), which have recently been associated with numerous potentially beneficial
617 618 619 620	Given the association we identified between somatic symptoms and FGF19 and FGF21, and these hormones and the effects of GLP-1 receptor agonists (Shao and Jin, 2022), which have recently been associated with numerous potentially beneficial mental health outcomes (Chen et al., 2024; Xie et al., 2025), another avenue might
617 618 619 620 621	Given the association we identified between somatic symptoms and FGF19 and FGF21, and these hormones and the effects of GLP-1 receptor agonists (Shao and Jin, 2022), which have recently been associated with numerous potentially beneficial mental health outcomes (Chen et al., 2024; Xie et al., 2025), another avenue might be to explore if depression with somatic symptoms is improved by GLP-1 receptor
617 618 619 620 621 622	Given the association we identified between somatic symptoms and FGF19 and FGF21, and these hormones and the effects of GLP-1 receptor agonists (Shao and Jin, 2022), which have recently been associated with numerous potentially beneficial mental health outcomes (Chen et al., 2024; Xie et al., 2025), another avenue might be to explore if depression with somatic symptoms is improved by GLP-1 receptor agonists.

624 studies in other cohort studies including UK Biobank (Sun et al., 2023), but gives

625 results on an arbitrary scale. For IL-6, a high correlation between a clinical chemistry

626 assay and Olink levels has been demonstrated in ALSPAC (Goulding et al., 2022).

627 However, Olink may differ in target epitopes to other assays (Eldjarn et al., 2023),

628 leading to only modest correlations with the SomaScan assay.

629 While the absolute values we report may not be generalisable, the pattern of change
630 in relative levels of immuno-metabolic variables may be relevant to studies using
631 other methods.

Donnelly et al: Immuno-metabolic Signatures of Depressive Symptoms

632	The ALSPAC study is not diverse in terms of ethnicity. Individuals who have
633	continued to participate into early adulthood tend to be women, come from more
634	educated and affluent backgrounds (Donnelly et al., 2022), and have a lower
635	prevalence of depressive symptoms (Office for National Statistics, 2021) than the
636	general UK population. Therefore, the generalisability of our findings to other
637	populations may be limited and our conclusions need to be externally validated in
638	populations with different characteristics, e.g. age, ethnicity and co-morbid health
639	conditions. Larger population sizes are also necessary to improve and validate
640	machine learning models.
641	Immuno-metabolic biomarkers were assayed at age 24. It is possible that
642	longitudinal trends in biomarker levels derived from repeated measurement could
643	yield more accurate prediction, but such datasets remain scarce e.g. (Palmer et al.,
644	2024; Perry et al., 2021a).
645	Our longitudinal follow-up data was limited to SMFQ scores. The SMFQ does not
646	include somatic symptoms. However, at present follow-up CIS-R data is not
647	available from ALSPAC. Additionally, although our sample size is reasonably large,
648	in a group of young adults a small number would be expected to develop psychiatric
649	disorders other than depression, including bipolar affective disorder and psychotic
650	disorders, but may be included in the depression group in the present data.
651	Future studies of longitudinal associations when more detailed psychiatric symptom
652	data are available will be invaluable in evaluating the association of immuno-
653	metabolic biomarkers with long-term trends in psychiatric symptoms.
654	Finally, our cross-sectional study was not designed, or able, to prove causal
055	
655	relationships or suggest mechanisms by which immune or metabolic dysfunction

Donnelly et al: Immuno-metabolic Signatures of Depressive Symptoms

- 656 might impact the brain systems involved in the manifestation of the subjective
- 657 experience of depression. Other study designs are necessary to explore this.

658 5. Conclusions

- 659 We found depression is associated with changes in multiple immuno-metabolic
- 660 markers. Specific patterns of immuno-metabolic biomarkers are associated with
- 661 differing subsets of depression symptoms (somatic-inflamed vs anxiety-non-
- 662 inflamed), which are potentially relevant for future symptom severity. Immuno-
- 663 metabolic biomarkers predict depression and high levels of somatic symptoms, but
- not anxiety symptoms, better than chance. Our results highlight the heterogeneity of
- 665 depression and opportunities for immuno-metabolic biomarker-based subtyping,
- 666 prediction and targeted intervention in future.

Donnelly et al: Immuno-metabolic Signatures of Depressive Symptoms

667 Acknowledgements

- 668 We are extremely grateful to all the families who took part in the ALSPAC cohort
- study, the midwives for their help in recruiting them, and the whole ALSPAC team,
- 670 which includes interviewers, computer and laboratory technicians, clerical workers,
- 671 research scientists, volunteers, managers, receptionists and nurses. The views
- 672 expressed are those of the authors and not necessarily those of the NIHR or the
- 673 Department of Health and Social Care.

674 Funding

- 675 GMK acknowledges funding support from the UK Medical Research Council (MRC),
- 676 grant number: MC_UU_00032/6, which forms part of the MRC Integrative
- 677 Epidemiology Unit at the University of Bristol. GMK also acknowledges funding from
- the Wellcome Trust (grant numbers: 201486/Z/16/Z and 201486/B/16/Z), the Medical
- 679 Research Council (grant numbers: MR/W014416/1; MR/S037675/1; and
- 680 MR/Z50354X/1), and the UK National Institute of Health and Care Research (NIHR)
- 681 Bristol Biomedical Research Centre (grant number: NIHR 203315). The views
- 682 expressed are those of the authors and not necessarily those of the UK NIHR or the
- 683 Department of Health and Social Care.
- 684 NAD was supported by an NIHR Clinical Lectureship in General Adult Psychiatry.
- 685 RSMT is supported by the Tackling Multimorbidity at Scale Strategic Priorities Fund
- 686 programme (MR/W014416/1).
- 687 ALM is supported by the Medical Research Council via the Integrative Epidemiology
- 688 Unit (MC_UU_00032/01).

Donnelly et al: Immuno-metabolic Signatures of Depressive Symptoms

- 689 The UK Medical Research Council and Wellcome Trust (Grant ref: 217065/Z/19/Z)
- and the University of Bristol provide core support for ALSPAC. A comprehensive list
- 691 of grants funding awarded to the ALSPAC study is available from ALSPAC website
- 692 (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf).
- 693 This publication is the work of the authors and NAD and GMK will serve as
- 694 guarantors for the contents of this paper.

695 Preprint

- An early version of this manuscript was deposited as a preprint to medRxiv:
- 697 <u>https://doi.org/10.1101/2024.06.03.24308351</u>

698 Data Availability

- 699 Data from the ALSPAC study is available via a managed open access system: in line
- with ALSPAC data access policy, all raw data used for this work can be accessed by
- 701 other investigators by making a request to the ALSPAC study executive (see the
- 702 study website: <u>http://www.bristol.ac.uk/alspac/researchers/access/</u>). Available
- 703 variables can be browsed via the ALSPAC data dictionary
- 704 (http://www.bristol.ac.uk/alspac/researchers/our-data/) and variable search
- 705 (<u>https://variables.alspac.bris.ac.uk/</u>).
- 706 Analysis scripts are available online: <u>https://github.com/NADonnelly/dep_infl</u>

707 Competing Interests

708 The authors have no competing interests to declare.

Donnelly et al: Immuno-metabolic Signatures of Depressive Symptoms

709 CRediT authorship statement

- 710 Donnelly N: Conceptualisation; Study design; Software; Data Curation; Formal
- 711 Analysis; Visualization; Writing Original Draft; Writing Reviewing & Editing
- 712 Tsang RSM: Writing Reviewing & Editing; Resources
- 713 Foley E: Writing Reviewing & Editing; Resources
- 714 Fraser H: Writing Reviewing & Editing; Resources
- 715 Hanson A: Writing Reviewing & Editing; Resources
- 716 Khandaker GM: Conceptualisation; Study design; Writing Reviewing & Editing;
- 717 Funding acquisition; Supervision

Donnelly et al: Immuno-metabolic Signatures of Depressive Symptoms

718 References

719	Agresta, L., Hoebe, K.H.N., Janssen, E.M., 2018. The Emerging Role of CD244
720	Signaling in Immune Cells of the Tumor Microenvironment. Front. Immunol. 9.
721	https://doi.org/10.3389/fimmu.2018.02809
722	Alba, A.C., Agoritsas, T., Walsh, M., Hanna, S., Iorio, A., Devereaux, P.J., McGinn,
723	T., Guyatt, G., 2017. Discrimination and Calibration of Clinical Prediction
724	Models: Users' Guides to the Medical Literature. JAMA 318. 1377–1384.
725	https://doi.org/10.1001/iama.2017.12126
726	Arribas, M., Barnby, J.M., Patel, R., McCutcheon, R.A., Kornblum, D., Shetty, H.,
727	Krakowski, K., Stahl, D., Koutsouleris, N., McGuire, P., Fusar-Poli, P., Oliver,
728	D., 2025. Longitudinal evolution of the transdiagnostic prodrome to severe
729	mental disorders: a dynamic temporal network analysis informed by natural
730	language processing and electronic health records. Mol. Psychiatry.
731	https://doi.org/10.1038/s41380-025-02896-3
732	Boca, S.M., Leek, J.T., 2018. A direct approach to estimating false discovery rates
733	conditional on covariates. PeerJ 6. e6035. https://doi.org/10.7717/peeri.6035
734	BonDurant, L.D., Potthoff, M.J., 2018, Fibroblast Growth Factor 21: A Versatile
735	Regulator of Metabolic Homeostasis, Annu, Rev. Nutr. 38, 173–196.
736	https://doi.org/10.1146/annurev-nutr-071816-064800
737	Bot. M., Milaneschi, Y., Al-Shehri, T., Amin, N., Garmaeva, S., Onderwater, G.L.J.,
738	Pool, R., Thesing, C.S., Viifhuizen, L.S., Vogelzangs, N., Arts, I.C.W.,
739	Demirkan, A., van Duijn, C., van Greevenbroek, M., van der Kallen, C.J.H.,
740	Köhler, S., Ligthart, L., van den Maagdenberg, A.M.J.M., Mook-Kanamori,
741	D.O., de Mutsert, R., Tiemeier, H., Schram, M.T., Stehouwer, C.D.A.,
742	Terwindt, G.M., Willems van Dijk, K., Fu, J., Zhernakova, A., Beekman, M.,
743	Slagboom, P.E., Boomsma, D.I., Penninx, B.W.J.H., BBMRI-NL Metabolomics
744	Consortium, 2020. Metabolomics Profile in Depression: A Pooled Analysis of
745	230 Metabolic Markers in 5283 Cases With Depression and 10,145 Controls.
746	Biol. Psychiatry 87, 409–418. https://doi.org/10.1016/j.biopsych.2019.08.016
747	Boyd, A., Golding, J., Macleod, J., Lawlor, D.A., Fraser, A., Henderson, J., Molloy,
748	L., Ness, A., Ring, S., Davey Smith, G., 2013. Cohort Profile: The 'Children of
749	the 90s'-the index offspring of the Avon Longitudinal Study of Parents and
750	Children. Int. J. Epidemiol. 42, 111–127. https://doi.org/10.1093/ije/dys064
751	Chen, X., Zhao, P., Wang, W., Guo, L., Pan, Q., 2024. The Antidepressant Effects of
752	GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis. Am. J.
753	Geriatr. Psychiatry Off. J. Am. Assoc. Geriatr. Psychiatry 32, 117–127.
754	https://doi.org/10.1016/j.jagp.2023.08.010
755	Chu, A.L., Stochl, J., Lewis, G., Zammit, S., Jones, P.B., Khandaker, G.M., 2019.
756	Longitudinal association between inflammatory markers and specific
757	symptoms of depression in a prospective birth cohort. Brain. Behav. Immun.
758	76, 74–81. https://doi.org/10.1016/j.bbi.2018.11.007
759	Davyson, E., Shen, X., Gadd, D.A., Bernabeu, E., Hillary, R.F., McCartney, D.L.,
760	Adams, M., Marioni, R., McIntosh, A.M., 2023. Metabolomic Investigation of
761	Major Depressive Disorder Identifies a Potentially Causal Association With
762	Polyunsaturated Fatty Acids. Biol. Psychiatry 94, 630–639.
763	https://doi.org/10.1016/j.biopsych.2023.01.027
764	Donnelly, N.A., Perry, B.I., Jones, H.J., Khandaker, G.M., 2022. Childhood immuno-
765	metabolic markers and risk of depression and psychosis in adulthood: A

766	prospective birth cohort study. Psychoneuroendocrinology 139, 105707.
767	https://doi.org/10.1016/j.psyneuen.2022.105707
768	Eldjarn, G.H., Ferkingstad, E., Lund, S.H., Helgason, H., Magnusson, O.T.,
769	Gunnarsdottir, K., Olafsdottir, T.A., Halldorsson, B.V., Olason, P.I., Zink, F.,
770	Gudjonsson, S.A., Sveinbjornsson, G., Magnusson, M.I., Helgason, A.,
771	Oddsson, A., Halldorsson, G.H., Magnusson, M.K., Saevarsdottir, S.,
772	Eiriksdottir, T., Masson, G., Stefansson, H., Jonsdottir, I., Holm, H., Rafnar,
773	T., Melsted, P., Saemundsdottir, J., Norddahl, G.L., Thorleifsson, G.,
774	Ulfarsson, M.O., Gudbjartsson, D.F., Thorsteinsdottir, U., Sulem, P.,
775	Stefansson, K., 2023. Large-scale plasma proteomics comparisons through
776	genetics and disease associations. Nature 622, 348–358.
777	https://doi.org/10.1038/s41586-023-06563-x
778	Foley, É.M., Parkinson, J.T., Mitchell, R.E., Turner, L., Khandaker, G.M., 2023.
779	Peripheral blood cellular immunophenotype in depression: a systematic
780	review and meta-analysis. Mol. Psychiatry 28, 1004–1019.
781	https://doi.org/10.1038/s41380-022-01919-7
782	Frank, P., Jokela, M., Batty, G.D., Cadar, D., Steptoe, A., Kivimäki, M., 2021.
783	Association Between Systemic Inflammation and Individual Symptoms of
784	Depression: A Pooled Analysis of 15 Population-Based Cohort Studies. Am.
785	J. Psychiatry 178, 1107–1118.
786	https://doi.org/10.1176/appi.ajp.2021.20121776
787	Fraser, A., Macdonald-Wallis, C., Tilling, K., Boyd, A., Golding, J., Davey Smith, G.,
788	Henderson, J., Macleod, J., Molloy, L., Ness, A., Ring, S., Nelson, S.M.,
789	Lawlor, D.A., 2013. Cohort Profile: The Avon Longitudinal Study of Parents
790	and Children: ALSPAC mothers cohort. Int. J. Epidemiol. 42, 97–110.
791	https://doi.org/10.1093/ije/dys066
792	Fu, C.H.Y., Antoniades, M., Erus, G., Garcia, J.A., Fan, Y., Arnone, D., Arnott, S.R.,
793	Chen, T., Choi, K.S., Fatt, C.C., Frey, B.N., Frokjaer, V.G., Ganz, M.,
794	Godlewska, B.R., Hassel, S., Ho, K., McIntosh, A.M., Qin, K., Rotzinger, S.,
795	Sacchet, M.D., Savitz, J., Shou, H., Singh, A., Stolicyn, A., Strigo, I., Strother,
796	S.C., Tosun, D., Victor, T.A., Wei, D., Wise, T., Zahn, R., Anderson, I.M.,
797	Craighead, W.E., Deakin, J.F.W., Dunlop, B.W., Elliott, R., Gong, Q., Gotlib,
798	I.H., Harmer, C.J., Kennedy, S.H., Knudsen, G.M., Mayberg, H.S., Paulus,
799	M.P., Qiu, J., Trivedi, M.H., Whalley, H.C., Yan, CG., Young, A.H.,
800	Davatzikos, C., 2024. Neuroanatomical dimensions in medication-free
801	individuals with major depressive disorder and treatment response to SSRI
802	antidepressant medications or placebo. Nat. Ment. Health 2, 164–176.
803	https://doi.org/10.1038/s44220-023-00187-w
804	Golding, Pembrey, Jones, Team, T.A.S., 2001. ALSPAC–The Avon Longitudinal
805	Study of Parents and Children. Paediatr. Perinat. Epidemiol. 15, 74–87.
806	https://doi.org/10.1046/j.1365-3016.2001.00325.x
807	Goldsmith, D.R., Rapaport, M.H., Miller, B.J., 2016. A meta-analysis of blood
808	cytokine network alterations in psychiatric patients: comparisons between
809	schizophrenia, bipolar disorder and depression. Mol. Psychiatry 21, 1696–
810	1709. https://doi.org/10.1038/mp.2016.3
811	Göteson, A., Isgren, A., Sparding, T., Holmén-Larsson, J., Jakobsson, J., Pålsson,
812	E., Landén, M., 2022. A serum proteomic study of two case-control cohorts
813	identifies novel biomarkers for bipolar disorder. Transl. Psychiatry 12, 55.
814	https://doi.org/10.1038/s41398-022-01819-y

815	Goulding, N., Goudswaard, L.J., Hughes, D.A., Corbin, L.J., Groom, A., Ring, S.,
816	Timpson, N.J., Fraser, A., Northstone, K., Suderman, M., 2022. Inflammation
817	proteomics datasets in the ALSPAC cohort [version 1; peer review: 1
818	approved, 1 approved with reservations]. Wellcome Open Res.
819	https://doi.org/10.12688/wellcomeopenres.18482.
820	Harris, P.A., Taylor, R., Minor, B.L., Elliott, V., Fernandez, M., O'Neal, L., McLeod,
821	L., Delacqua, G., Delacqua, F., Kirby, J., Duda, S.N., REDCap Consortium,
822	2019. The REDCap consortium: Building an international community of
823	software platform partners, J. Biomed. Inform, 95, 103208.
824	https://doi.org/10.1016/i.jbj.2019.103208
825	Harris, P.A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., Conde, J.G., 2009.
826	Research electronic data capture (REDCap)a metadata-driven methodology
827	and workflow process for providing translational research informatics support.
828	I Riomed Inform 42 377–381 https://doi.org/10.1016/j.jbj.2008.08.010
829	Houtepen I. C. Heron J. Suderman M.I. Tilling K. Howe I. D. 2018 Adverse
830	childhood experiences in the children of the Avon Longitudinal Study of
831	Parents and Children (AI SPAC), Wellcome Open Res. 3, 106
832	https://doi.org/10.12688/wellcomeonenres.1/716.1
833	Jansan S.B. Shaikh M.A. Akkouh J.A. Szaba A. O'Connell K.S. Lakva T.
000	Englishi, S.D., Sheikh, M.A., Akkoun, I.A., Szabo, A., O'Connell, N.S., Lekva, T.,
835	Lingh, J.A., Agailz, I., Elvsashagen, T., Onnerou, M.D.L.O., Weibell, M.A., Johnson E. Kroken P.A. Melle I. Drange O.K. Marland T. Vaaler A.E.
838	Mostlyo LT Aukrust P. Diurovic S. Eiol Stoop N. Androsson O.A.
030 927	Holand T 2022 Elevated Systemic Levels of Markers Deflecting Intestinal
020	Barrier Dysfunction and Inflammasame Activation Are Correlated in Sovera
000	Montol Illinoon Sobizonbr Pull 40,625,645
039	Meritai niness. Schizophi. Buil. 49, 033–045.
010	https://doi.org/10.1002/cohbul/chao101
840	https://doi.org/10.1093/schbul/sbac191
840 841 842	https://doi.org/10.1093/schbul/sbac191 Kappelmann, N., Arloth, J., Georgakis, M.K., Czamara, D., Rost, N., Ligthart, S., Khandakar, G.M., Binder, F.R., 2021, Disperting the Association Between
840 841 842 843	https://doi.org/10.1093/schbul/sbac191 Kappelmann, N., Arloth, J., Georgakis, M.K., Czamara, D., Rost, N., Ligthart, S., Khandaker, G.M., Binder, E.B., 2021. Dissecting the Association Between Inflammation Metabolic Disrogulation and Specific Depressive Symptoms: A
840 841 842 843	https://doi.org/10.1093/schbul/sbac191 Kappelmann, N., Arloth, J., Georgakis, M.K., Czamara, D., Rost, N., Ligthart, S., Khandaker, G.M., Binder, E.B., 2021. Dissecting the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive Symptoms: A Constin Correlation and 2 Sample Mondelian Bandemization Study, IAMA
840 841 842 843 844 844	https://doi.org/10.1093/schbul/sbac191 Kappelmann, N., Arloth, J., Georgakis, M.K., Czamara, D., Rost, N., Ligthart, S., Khandaker, G.M., Binder, E.B., 2021. Dissecting the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive Symptoms: A Genetic Correlation and 2-Sample Mendelian Randomization Study. JAMA
840 841 842 843 844 845 845	 https://doi.org/10.1093/schbul/sbac191 Kappelmann, N., Arloth, J., Georgakis, M.K., Czamara, D., Rost, N., Ligthart, S., Khandaker, G.M., Binder, E.B., 2021. Dissecting the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive Symptoms: A Genetic Correlation and 2-Sample Mendelian Randomization Study. JAMA Psychiatry 78, 161–170. https://doi.org/10.1001/jamapsychiatry.2020.3436 Kir S. Baddaw, S.A. Samuel, V.T. Miller, P. Provin, S.F. Swing, Pawell, K. Yu.
840 841 842 843 844 845 846 847	 https://doi.org/10.1093/schbul/sbac191 Kappelmann, N., Arloth, J., Georgakis, M.K., Czamara, D., Rost, N., Ligthart, S., Khandaker, G.M., Binder, E.B., 2021. Dissecting the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive Symptoms: A Genetic Correlation and 2-Sample Mendelian Randomization Study. JAMA Psychiatry 78, 161–170. https://doi.org/10.1001/jamapsychiatry.2020.3436 Kir, S., Beddow, S.A., Samuel, V.T., Miller, P., Previs, S.F., Suino-Powell, K., Xu,
840 841 842 843 844 845 846 847	 https://doi.org/10.1093/schbul/sbac191 Kappelmann, N., Arloth, J., Georgakis, M.K., Czamara, D., Rost, N., Ligthart, S., Khandaker, G.M., Binder, E.B., 2021. Dissecting the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive Symptoms: A Genetic Correlation and 2-Sample Mendelian Randomization Study. JAMA Psychiatry 78, 161–170. https://doi.org/10.1001/jamapsychiatry.2020.3436 Kir, S., Beddow, S.A., Samuel, V.T., Miller, P., Previs, S.F., Suino-Powell, K., Xu, H.E., Shulman, G.I., Kliewer, S.A., Mangelsdorf, D.J., 2011. FGF19 as a Destermention.
840 841 842 843 844 845 846 846 847 848	 https://doi.org/10.1093/schbul/sbac191 Kappelmann, N., Arloth, J., Georgakis, M.K., Czamara, D., Rost, N., Ligthart, S., Khandaker, G.M., Binder, E.B., 2021. Dissecting the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive Symptoms: A Genetic Correlation and 2-Sample Mendelian Randomization Study. JAMA Psychiatry 78, 161–170. https://doi.org/10.1001/jamapsychiatry.2020.3436 Kir, S., Beddow, S.A., Samuel, V.T., Miller, P., Previs, S.F., Suino-Powell, K., Xu, H.E., Shulman, G.I., Kliewer, S.A., Mangelsdorf, D.J., 2011. FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen
840 841 842 843 844 845 846 845 846 847 848 849 850	 https://doi.org/10.1093/schbul/sbac191 Kappelmann, N., Arloth, J., Georgakis, M.K., Czamara, D., Rost, N., Ligthart, S., Khandaker, G.M., Binder, E.B., 2021. Dissecting the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive Symptoms: A Genetic Correlation and 2-Sample Mendelian Randomization Study. JAMA Psychiatry 78, 161–170. https://doi.org/10.1001/jamapsychiatry.2020.3436 Kir, S., Beddow, S.A., Samuel, V.T., Miller, P., Previs, S.F., Suino-Powell, K., Xu, H.E., Shulman, G.I., Kliewer, S.A., Mangelsdorf, D.J., 2011. FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis. Science 331, 1621–1624. https://doi.org/10.1126/science.1198363
840 841 842 843 844 845 846 845 846 847 848 849 850	 https://doi.org/10.1093/schbul/sbac191 Kappelmann, N., Arloth, J., Georgakis, M.K., Czamara, D., Rost, N., Ligthart, S., Khandaker, G.M., Binder, E.B., 2021. Dissecting the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive Symptoms: A Genetic Correlation and 2-Sample Mendelian Randomization Study. JAMA Psychiatry 78, 161–170. https://doi.org/10.1001/jamapsychiatry.2020.3436 Kir, S., Beddow, S.A., Samuel, V.T., Miller, P., Previs, S.F., Suino-Powell, K., Xu, H.E., Shulman, G.I., Kliewer, S.A., Mangelsdorf, D.J., 2011. FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis. Science 331, 1621–1624. https://doi.org/10.1126/science.1198363 Korthauer, K., Kimes, P.K., Duvallet, C., Reyes, A., Subramanian, A., Teng, M.,
840 841 842 843 844 845 846 845 846 847 848 849 850 851 851	 https://doi.org/10.1093/schbul/sbac191 Kappelmann, N., Arloth, J., Georgakis, M.K., Czamara, D., Rost, N., Ligthart, S., Khandaker, G.M., Binder, E.B., 2021. Dissecting the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive Symptoms: A Genetic Correlation and 2-Sample Mendelian Randomization Study. JAMA Psychiatry 78, 161–170. https://doi.org/10.1001/jamapsychiatry.2020.3436 Kir, S., Beddow, S.A., Samuel, V.T., Miller, P., Previs, S.F., Suino-Powell, K., Xu, H.E., Shulman, G.I., Kliewer, S.A., Mangelsdorf, D.J., 2011. FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis. Science 331, 1621–1624. https://doi.org/10.1126/science.1198363 Korthauer, K., Kimes, P.K., Duvallet, C., Reyes, A., Subramanian, A., Teng, M., Shukla, C., Alm, E.J., Hicks, S.C., 2019. A practical guide to methods
840 841 842 843 844 845 846 847 848 849 850 851 852	 https://doi.org/10.1093/schbul/sbac191 Kappelmann, N., Arloth, J., Georgakis, M.K., Czamara, D., Rost, N., Ligthart, S., Khandaker, G.M., Binder, E.B., 2021. Dissecting the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive Symptoms: A Genetic Correlation and 2-Sample Mendelian Randomization Study. JAMA Psychiatry 78, 161–170. https://doi.org/10.1001/jamapsychiatry.2020.3436 Kir, S., Beddow, S.A., Samuel, V.T., Miller, P., Previs, S.F., Suino-Powell, K., Xu, H.E., Shulman, G.I., Kliewer, S.A., Mangelsdorf, D.J., 2011. FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis. Science 331, 1621–1624. https://doi.org/10.1126/science.1198363 Korthauer, K., Kimes, P.K., Duvallet, C., Reyes, A., Subramanian, A., Teng, M., Shukla, C., Alm, E.J., Hicks, S.C., 2019. A practical guide to methods controlling false discoveries in computational biology. Genome Biol. 20, 118.
840 841 842 843 844 845 846 845 846 847 848 849 850 851 852 853	 https://doi.org/10.1093/schbul/sbac191 Kappelmann, N., Arloth, J., Georgakis, M.K., Czamara, D., Rost, N., Ligthart, S., Khandaker, G.M., Binder, E.B., 2021. Dissecting the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive Symptoms: A Genetic Correlation and 2-Sample Mendelian Randomization Study. JAMA Psychiatry 78, 161–170. https://doi.org/10.1001/jamapsychiatry.2020.3436 Kir, S., Beddow, S.A., Samuel, V.T., Miller, P., Previs, S.F., Suino-Powell, K., Xu, H.E., Shulman, G.I., Kliewer, S.A., Mangelsdorf, D.J., 2011. FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis. Science 331, 1621–1624. https://doi.org/10.1126/science.1198363 Korthauer, K., Kimes, P.K., Duvallet, C., Reyes, A., Subramanian, A., Teng, M., Shukla, C., Alm, E.J., Hicks, S.C., 2019. A practical guide to methods controlling false discoveries in computational biology. Genome Biol. 20, 118. https://doi.org/10.1186/s13059-019-1716-1
840 841 842 843 844 845 846 847 848 849 850 851 852 853 854	 https://doi.org/10.1093/schbul/sbac191 Kappelmann, N., Arloth, J., Georgakis, M.K., Czamara, D., Rost, N., Ligthart, S., Khandaker, G.M., Binder, E.B., 2021. Dissecting the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive Symptoms: A Genetic Correlation and 2-Sample Mendelian Randomization Study. JAMA Psychiatry 78, 161–170. https://doi.org/10.1001/jamapsychiatry.2020.3436 Kir, S., Beddow, S.A., Samuel, V.T., Miller, P., Previs, S.F., Suino-Powell, K., Xu, H.E., Shulman, G.I., Kliewer, S.A., Mangelsdorf, D.J., 2011. FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis. Science 331, 1621–1624. https://doi.org/10.1126/science.1198363 Korthauer, K., Kimes, P.K., Duvallet, C., Reyes, A., Subramanian, A., Teng, M., Shukla, C., Alm, E.J., Hicks, S.C., 2019. A practical guide to methods controlling false discoveries in computational biology. Genome Biol. 20, 118. https://doi.org/10.1186/s13059-019-1716-1 Lamers, F., Milaneschi, Y., Vinkers, C.H., Schoevers, R.A., Giltay, E.J., Penninx,
840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855	 https://doi.org/10.1093/schbul/sbac191 Kappelmann, N., Arloth, J., Georgakis, M.K., Czamara, D., Rost, N., Ligthart, S., Khandaker, G.M., Binder, E.B., 2021. Dissecting the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive Symptoms: A Genetic Correlation and 2-Sample Mendelian Randomization Study. JAMA Psychiatry 78, 161–170. https://doi.org/10.1001/jamapsychiatry.2020.3436 Kir, S., Beddow, S.A., Samuel, V.T., Miller, P., Previs, S.F., Suino-Powell, K., Xu, H.E., Shulman, G.I., Kliewer, S.A., Mangelsdorf, D.J., 2011. FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis. Science 331, 1621–1624. https://doi.org/10.1126/science.1198363 Korthauer, K., Kimes, P.K., Duvallet, C., Reyes, A., Subramanian, A., Teng, M., Shukla, C., Alm, E.J., Hicks, S.C., 2019. A practical guide to methods controlling false discoveries in computational biology. Genome Biol. 20, 118. https://doi.org/10.1186/s13059-019-1716-1 Lamers, F., Milaneschi, Y., Vinkers, C.H., Schoevers, R.A., Giltay, E.J., Penninx, B.W.J.H., 2020. Depression profilers and immuno-metabolic dysregulation:
840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856	 https://doi.org/10.1093/schbul/sbac191 Kappelmann, N., Arloth, J., Georgakis, M.K., Czamara, D., Rost, N., Ligthart, S., Khandaker, G.M., Binder, E.B., 2021. Dissecting the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive Symptoms: A Genetic Correlation and 2-Sample Mendelian Randomization Study. JAMA Psychiatry 78, 161–170. https://doi.org/10.1001/jamapsychiatry.2020.3436 Kir, S., Beddow, S.A., Samuel, V.T., Miller, P., Previs, S.F., Suino-Powell, K., Xu, H.E., Shulman, G.I., Kliewer, S.A., Mangelsdorf, D.J., 2011. FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis. Science 331, 1621–1624. https://doi.org/10.1126/science.1198363 Korthauer, K., Kimes, P.K., Duvallet, C., Reyes, A., Subramanian, A., Teng, M., Shukla, C., Alm, E.J., Hicks, S.C., 2019. A practical guide to methods controlling false discoveries in computational biology. Genome Biol. 20, 118. https://doi.org/10.1186/s13059-019-1716-1 Lamers, F., Milaneschi, Y., Vinkers, C.H., Schoevers, R.A., Giltay, E.J., Penninx, B.W.J.H., 2020. Depression profilers and immuno-metabolic dysregulation: Longitudinal results from the NESDA study. Brain. Behav. Immun. 88, 174–
840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857	 https://doi.org/10.1093/schbul/sbac191 Kappelmann, N., Arloth, J., Georgakis, M.K., Czamara, D., Rost, N., Ligthart, S., Khandaker, G.M., Binder, E.B., 2021. Dissecting the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive Symptoms: A Genetic Correlation and 2-Sample Mendelian Randomization Study. JAMA Psychiatry 78, 161–170. https://doi.org/10.1001/jamapsychiatry.2020.3436 Kir, S., Beddow, S.A., Samuel, V.T., Miller, P., Previs, S.F., Suino-Powell, K., Xu, H.E., Shulman, G.I., Kliewer, S.A., Mangelsdorf, D.J., 2011. FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis. Science 331, 1621–1624. https://doi.org/10.1126/science.1198363 Korthauer, K., Kimes, P.K., Duvallet, C., Reyes, A., Subramanian, A., Teng, M., Shukla, C., Alm, E.J., Hicks, S.C., 2019. A practical guide to methods controlling false discoveries in computational biology. Genome Biol. 20, 118. https://doi.org/10.1186/s13059-019-1716-1 Lamers, F., Milaneschi, Y., Vinkers, C.H., Schoevers, R.A., Giltay, E.J., Penninx, B.W.J.H., 2020. Depression profilers and immuno-metabolic dysregulation: Longitudinal results from the NESDA study. Brain. Behav. Immun. 88, 174–183. https://doi.org/10.1016/j.bbi.2020.04.002
840 841 842 843 844 845 846 847 848 847 848 849 850 851 852 853 854 855 856 857 858	 https://doi.org/10.1093/schbul/sbac191 Kappelmann, N., Arloth, J., Georgakis, M.K., Czamara, D., Rost, N., Ligthart, S., Khandaker, G.M., Binder, E.B., 2021. Dissecting the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive Symptoms: A Genetic Correlation and 2-Sample Mendelian Randomization Study. JAMA Psychiatry 78, 161–170. https://doi.org/10.1001/jamapsychiatry.2020.3436 Kir, S., Beddow, S.A., Samuel, V.T., Miller, P., Previs, S.F., Suino-Powell, K., Xu, H.E., Shulman, G.I., Kliewer, S.A., Mangelsdorf, D.J., 2011. FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis. Science 331, 1621–1624. https://doi.org/10.1126/science.1198363 Korthauer, K., Kimes, P.K., Duvallet, C., Reyes, A., Subramanian, A., Teng, M., Shukla, C., Alm, E.J., Hicks, S.C., 2019. A practical guide to methods controlling false discoveries in computational biology. Genome Biol. 20, 118. https://doi.org/10.1186/s13059-019-1716-1 Lamers, F., Milaneschi, Y., Vinkers, C.H., Schoevers, R.A., Giltay, E.J., Penninx, B.W.J.H., 2020. Depression profilers and immuno-metabolic dysregulation: Longitudinal results from the NESDA study. Brain. Behav. Immun. 88, 174–183. https://doi.org/10.1016/j.bbi.2020.04.002 Lewis, G., Pelosi, A.J., Araya, R., Dunn, G., 1992. Measuring psychiatric disorder in
840 841 842 843 844 845 846 847 848 847 848 849 850 851 852 853 854 855 856 857 858 859	 https://doi.org/10.1093/schbul/sbac191 Kappelmann, N., Arloth, J., Georgakis, M.K., Czamara, D., Rost, N., Ligthart, S., Khandaker, G.M., Binder, E.B., 2021. Dissecting the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive Symptoms: A Genetic Correlation and 2-Sample Mendelian Randomization Study. JAMA Psychiatry 78, 161–170. https://doi.org/10.1001/jamapsychiatry.2020.3436 Kir, S., Beddow, S.A., Samuel, V.T., Miller, P., Previs, S.F., Suino-Powell, K., Xu, H.E., Shulman, G.I., Kliewer, S.A., Mangelsdorf, D.J., 2011. FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis. Science 331, 1621–1624. https://doi.org/10.1126/science.1198363 Korthauer, K., Kimes, P.K., Duvallet, C., Reyes, A., Subramanian, A., Teng, M., Shukla, C., Alm, E.J., Hicks, S.C., 2019. A practical guide to methods controlling false discoveries in computational biology. Genome Biol. 20, 118. https://doi.org/10.1186/s13059-019-1716-1 Lamers, F., Milaneschi, Y., Vinkers, C.H., Schoevers, R.A., Giltay, E.J., Penninx, B.W.J.H., 2020. Depression profilers and immuno-metabolic dysregulation: Longitudinal results from the NESDA study. Brain. Behav. Immun. 88, 174–183. https://doi.org/10.1016/j.bbi.2020.04.002 Lewis, G., Pelosi, A.J., Araya, R., Dunn, G., 1992. Measuring psychiatric disorder in the community: a standardized assessment for use by lay interviewers.
840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860	 https://doi.org/10.1093/schbul/sbac191 Kappelmann, N., Arloth, J., Georgakis, M.K., Czamara, D., Rost, N., Ligthart, S., Khandaker, G.M., Binder, E.B., 2021. Dissecting the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive Symptoms: A Genetic Correlation and 2-Sample Mendelian Randomization Study. JAMA Psychiatry 78, 161–170. https://doi.org/10.1001/jamapsychiatry.2020.3436 Kir, S., Beddow, S.A., Samuel, V.T., Miller, P., Previs, S.F., Suino-Powell, K., Xu, H.E., Shulman, G.I., Kliewer, S.A., Mangelsdorf, D.J., 2011. FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis. Science 331, 1621–1624. https://doi.org/10.1126/science.1198363 Korthauer, K., Kimes, P.K., Duvallet, C., Reyes, A., Subramanian, A., Teng, M., Shukla, C., Alm, E.J., Hicks, S.C., 2019. A practical guide to methods controlling false discoveries in computational biology. Genome Biol. 20, 118. https://doi.org/10.1186/s13059-019-1716-1 Lamers, F., Milaneschi, Y., Vinkers, C.H., Schoevers, R.A., Giltay, E.J., Penninx, B.W.J.H., 2020. Depression profilers and immuno-metabolic dysregulation: Longitudinal results from the NESDA study. Brain. Behav. Immun. 88, 174–183. https://doi.org/10.1016/j.bbi.2020.04.002 Lewis, G., Pelosi, A.J., Araya, R., Dunn, G., 1992. Measuring psychiatric disorder in the community: a standardized assessment for use by lay interviewers. Psychol. Med. 22, 465–486. https://doi.org/10.1017/s0033291700030415
840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861	 https://doi.org/10.1093/schbul/sbac191 Kappelmann, N., Arloth, J., Georgakis, M.K., Czamara, D., Rost, N., Ligthart, S., Khandaker, G.M., Binder, E.B., 2021. Dissecting the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive Symptoms: A Genetic Correlation and 2-Sample Mendelian Randomization Study. JAMA Psychiatry 78, 161–170. https://doi.org/10.1001/jamapsychiatry.2020.3436 Kir, S., Beddow, S.A., Samuel, V.T., Miller, P., Previs, S.F., Suino-Powell, K., Xu, H.E., Shulman, G.I., Kliewer, S.A., Mangelsdorf, D.J., 2011. FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis. Science 331, 1621–1624. https://doi.org/10.1126/science.1198363 Korthauer, K., Kimes, P.K., Duvallet, C., Reyes, A., Subramanian, A., Teng, M., Shukla, C., Alm, E.J., Hicks, S.C., 2019. A practical guide to methods controlling false discoveries in computational biology. Genome Biol. 20, 118. https://doi.org/10.1186/s13059-019-1716-1 Lamers, F., Milaneschi, Y., Vinkers, C.H., Schoevers, R.A., Giltay, E.J., Penninx, B.W.J.H., 2020. Depression profilers and immuno-metabolic dysregulation: Longitudinal results from the NESDA study. Brain. Behav. Immun. 88, 174–183. https://doi.org/10.1016/j.bbi.2020.04.002 Lewis, G., Pelosi, A.J., Araya, R., Dunn, G., 1992. Measuring psychiatric disorder in the community: a standardized assessment for use by lay interviewers. Psychol. Med. 22, 465–486. https://doi.org/10.1017/s0033291700030415 Lynall, ME., Turner, L., Bhatti, J., Cavanagh, J., de Boer, P., Mondelli, V., Jones,
840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862	 https://doi.org/10.1093/schbul/sbac191 Kappelmann, N., Arloth, J., Georgakis, M.K., Czamara, D., Rost, N., Ligthart, S., Khandaker, G.M., Binder, E.B., 2021. Dissecting the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive Symptoms: A Genetic Correlation and 2-Sample Mendelian Randomization Study. JAMA Psychiatry 78, 161–170. https://doi.org/10.1001/jamapsychiatry.2020.3436 Kir, S., Beddow, S.A., Samuel, V.T., Miller, P., Previs, S.F., Suino-Powell, K., Xu, H.E., Shulman, G.I., Kliewer, S.A., Mangelsdorf, D.J., 2011. FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis. Science 331, 1621–1624. https://doi.org/10.1126/science.1198363 Korthauer, K., Kimes, P.K., Duvallet, C., Reyes, A., Subramanian, A., Teng, M., Shukla, C., Alm, E.J., Hicks, S.C., 2019. A practical guide to methods controlling false discoveries in computational biology. Genome Biol. 20, 118. https://doi.org/10.1186/s13059-019-1716-1 Lamers, F., Milaneschi, Y., Vinkers, C.H., Schoevers, R.A., Giltay, E.J., Penninx, B.W.J.H., 2020. Depression profilers and immuno-metabolic dysregulation: Longitudinal results from the NESDA study. Brain. Behav. Immun. 88, 174–183. https://doi.org/10.1016/j.bbi.2020.04.002 Lewis, G., Pelosi, A.J., Araya, R., Dunn, G., 1992. Measuring psychiatric disorder in the community: a standardized assessment for use by lay interviewers. Psychol. Med. 22, 465–486. https://doi.org/10.1017/s0033291700030415 Lynall, ME., Turner, L., Bhatti, J., Cavanagh, J., de Boer, P., Mondelli, V., Jones, D., Drevets, W.C., Cowen, P., Harrison, N.A., Pariante, C.M., Pointon, L.,
840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863	 https://doi.org/10.1093/schbul/sbac191 Kappelmann, N., Arloth, J., Georgakis, M.K., Czamara, D., Rost, N., Ligthart, S., Khandaker, G.M., Binder, E.B., 2021. Dissecting the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive Symptoms: A Genetic Correlation and 2-Sample Mendelian Randomization Study. JAMA Psychiatry 78, 161–170. https://doi.org/10.1001/jamapsychiatry.2020.3436 Kir, S., Beddow, S.A., Samuel, V.T., Miller, P., Previs, S.F., Suino-Powell, K., Xu, H.E., Shulman, G.I., Kliewer, S.A., Mangelsdorf, D.J., 2011. FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis. Science 331, 1621–1624. https://doi.org/10.1126/science.1198363 Korthauer, K., Kimes, P.K., Duvallet, C., Reyes, A., Subramanian, A., Teng, M., Shukla, C., Alm, E.J., Hicks, S.C., 2019. A practical guide to methods controlling false discoveries in computational biology. Genome Biol. 20, 118. https://doi.org/10.1186/s13059-019-1716-1 Lamers, F., Milaneschi, Y., Vinkers, C.H., Schoevers, R.A., Giltay, E.J., Penninx, B.W.J.H., 2020. Depression profilers and immuno-metabolic dysregulation: Longitudinal results from the NESDA study. Brain. Behav. Immun. 88, 174–183. https://doi.org/10.1016/j.bbi.2020.04.002 Lewis, G., Pelosi, A.J., Araya, R., Dunn, G., 1992. Measuring psychiatric disorder in the community: a standardized assessment for use by lay interviewers. Psychol. Med. 22, 465–486. https://doi.org/10.1017/s0033291700030415 Lynall, ME., Turner, L., Bhatti, J., Cavanagh, J., de Boer, P., Mondelli, V., Jones, D., Drevets, W.C., Cowen, P., Harrison, N.A., Pariante, C.M., Pointon, L., Clatworthy, M.R., Bullmore, E., Neuroimmunology of Mood Disorders and

865	Stratified Subgroups of Inflamed Depression. Biol. Psychiatry 88, 185–196.
866	https://doi.org/10.1016/j.biopsych.2019.11.017
867	Milaneschi, Y., Kappelmann, N., Ye, Z., Lamers, F., Moser, S., Jones, P.B., Burgess,
868	S., Penninx, B.W.J.H., Khandaker, G.M., 2021. Association of inflammation
869	with depression and anxiety: evidence for symptom-specificity and potential
870	causality from UK Biobank and NESDA cohorts. Mol. Psychiatry.
871	https://doi.org/10.1038/s41380-021-01188-w
872	Mossaheb, N., Becker, J., Schaefer, M.R., Klier, C.M., Schloegelhofer, M.,
873	Papageorgiou, K., Amminger, G.P., 2012, The Community Assessment of
874	Psychic Experience (CAPE) guestionnaire as a screening-instrument in the
875	detection of individuals at ultra-high risk for psychosis. Schizophr. Res. 141.
876	210–214. https://doi.org/10.1016/i.schres.2012.08.008
877	Northstone, K., Lewcock, M., Groom, A., Boyd, A., Macleod, J., Timpson, N., Wells,
878	N 2019 The Avon Longitudinal Study of Parents and Children (ALSPAC): an
879	undate on the enrolled sample of index children in 2019. Wellcome Open Res
880	4 51 https://doi.org/10.12688/wellcomeonenres 15132.1
881	Office for National Statistics 2021 Depression or anxiety in adults. Great Britain: 22
882	September to 3 October 2021 [W/W/W Document] LIRI
883	https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/
884	mentalbealth/adbocs/1384/depressionoranyietvinadultsgreathritain22septem
885	herto3october2021 (accessed 11 12 23)
886	Osimo E E Dillinger T Rodriguez I M Khandaker G M Pariante C M Howes
000 997	O D 2020 Inflammatory markers in depression: A meta analysis of mean
007	differences and variability in 5 166 patients and 5 082 controls. Brain, Bobay
000	Immun 97 001 000 https://doi.org/10.1016/j.bbi.2020.02.010
009	Palmar E. P. Maralas Muñaz I. Darry P.I. Marwaha S. Warwick E. Pagara
090	Failurei, E.K., Morales-Murioz, I., Feiry, D.I., Marwara, S., Warwick, E., Rogers,
001	J.C., Optilegiove, R., 2024. Hajectories of Inflammation in Youth and Risk of Montal and Cardiamatabalia Disordars in Adulthaad. JAMA Davabiatry 91
092	1120, 1127, https://doi.org/10.1001/jomonou/objetry 2024.2102
090	Parry PL Stoch L Unthogray P. Zammit S. Wardham N. Langapharg C.
094	Minpappy E Dunger D Jones D Khandeker C M 2021a Longitudine
090	Tranda in Childhand Insulin Loyala and Rady Mass Index and Associations
090	With Disks of Developing and Depression in Young Adulta, IAMA Developing
000	with Risks of Psychosis and Depression in Young Adults. JAWA Psychiatry.
898	nttps://doi.org/10.1001/jamapsychiatry.2020.4180
899	Perry, B.I., Optnegrove, R., Kappelmann, N., Jones, P.B., Burgess, S., Knandaker,
900	G.M., 2021b. Associations of Immunological Proteins/ I raits with
901	Schizophrenia, Major Depression and Bipolar Disorder: A Bi-Directional Two-
902	Sample Mendelian Randomization Study. Brain. Behav. Immun. 97, 176–185.
903	https://doi.org/10.1016/j.bbi.2021.07.009
904	Poletti, S., Vai, B., Mazza, M.G., Zanardi, R., Lorenzi, C., Calesella, F., Cazzetta, S.,
905	Branchi, I., Colombo, C., Furlan, R., Benedetti, F., 2021. A peripheral
906	inflammatory signature discriminates bipolar from unipolar depression: A
907	machine learning approach. Prog. Neuropsychopharmacol. Biol. Psychiatry
908	105, 110136. https://doi.org/10.1016/j.pnpbp.2020.110136
909	Post, A., Dam, W.A., Sokooti, S., Groothof, D., Gloerich, J., van Gool, A.J., Kremer,
910	D., Gansevoort, R.T., van den Born, J., Kema, I.P., Franssen, C.F.M.,
911	Dullaart, R.P.F., Bakker, S.J.L., 2023. Circulating FGF21 Concentration,
912	Fasting Plasma Glucose, and the Risk of Type 2 Diabetes: Results From the
913	PREVEND Study. J. Clin. Endocrinol. Metab. 108, 1387–1393.
914	https://doi.org/10.1210/clinem/dgac729

915	Price, G.D., Collins, A.C., Mackin, D.M., Heinz, M.V., Jacobson, N.C., 2025. Use of
916	passively collected actigraphy data to detect individual depressive symptoms
917	in a clinical subpopulation and a general population. J. Psychopathol. Clin.
918	Sci. 134, 31–40. https://doi.org/10.1037/abn0000933
919	R Development Core Team, 2017. R: A Language and environment for statistical
920	computing. Vienna Austria R Found. Stat. Comput.
921	Rhew, I.C., Simpson, K., Tracy, M., Lymp, J., McCauley, E., Tsuang, D., Stoep, A.V.,
922	2010. Criterion validity of the Short Mood and Feelings Questionnaire and
923	one- and two-item depression screens in young adolescents. Child Adolesc.
924	Psychiatry Ment, Health 4, 8, https://doi.org/10.1186/1753-2000-4-8
925	Rohart, F., Gautier, B., Singh, A., Lê Cao, KA., 2017, mixOmics; An R package for
926	omics feature selection and multiple data integration. PLoS Comput. Biol. 13.
927	e1005752. https://doi.org/10.1371/iournal.pcbi.1005752
928	Segal, A., Parkes, L., Aguino, K., Kia, S.M., Wolfers, T., Franke, B., Hoogman, M.,
929	Beckmann, C.F., Westlve, L.T., Andreassen, O.A., Zalesky, A., Harrison, B.J.,
930	Davey, C.G., Soriano-Mas, C., Cardoner, N., Tiego, J., Yücel, M., Braganza.
931	L., Suo, C., Berk, M., Cotton, S., Bellgrove, M.A., Marguand, A.F., Fornito, A.,
932	2023. Regional, circuit and network heterogeneity of brain abnormalities in
933	psychiatric disorders. Nat. Neurosci. 1–17. https://doi.org/10.1038/s41593-
934	023-01404-6
935	Shao, W., Jin, T., 2022. Hepatic hormone FGF21 and its analogues in clinical trials.
936	Chronic Dis. Transl. Med. 8, 19–25.
937	https://doi.org/10.1016/j.cdtm.2021.08.005
938	Sun, B.B., Chiou, J., Traylor, M., Benner, C., Hsu, YH., Richardson, T.G.,
939	Surendran, P., Mahajan, A., Robins, C., Vasquez-Grinnell, S.G., Hou, L.,
940	Kvikstad, E.M., Burren, O.S., Davitte, J., Ferber, K.L., Gillies, C.E., Hedman,
941	Å.K., Hu, S., Lin, T., Mikkilineni, R., Pendergrass, R.K., Pickering, C., Prins,
942	B., Baird, D., Chen, CY., Ward, L.D., Deaton, A.M., Welsh, S., Willis, C.M.,
943	Lehner, N., Arnold, M., Wörheide, M.A., Suhre, K., Kastenmüller, G., Sethi, A.,
944	Cule, M., Raj, A., Kang, Hyun Ming, Burkitt-Gray, L., Melamud, E., Black,
945	M.H., Fauman, E.B., Howson, J.M.M., Kang, Hyun Min, McCarthy, M.I., Nioi,
946	P., Petrovski, S., Scott, R.A., Smith, E.N., Szalma, S., Waterworth, D.M.,
947	Mitnaul, L.J., Szustakowski, J.D., Gibson, B.W., Miller, M.R., Whelan, C.D.,
948	2023. Plasma proteomic associations with genetics and health in the UK
949	Biobank. Nature 622, 329-338. https://doi.org/10.1038/s41586-023-06592-6
950	Tennant, P.W.G., Murray, E.J., Arnold, K.F., Berrie, L., Fox, M.P., Gadd, S.C.,
951	Harrison, W.J., Keeble, C., Ranker, L.R., Textor, J., Tomova, G.D., Gilthorpe,
952	M.S., Ellison, G.T.H., 2021. Use of directed acyclic graphs (DAGs) to identify
953	confounders in applied health research: review and recommendations. Int. J.
954	Epidemiol. 50, 620–632. https://doi.org/10.1093/ije/dyaa213
955	Thorp, J.G., Marees, A.T., Ong, JS., An, J., MacGregor, S., Derks, E.M., 2020.
956	Genetic heterogeneity in self-reported depressive symptoms identified
957	through genetic analyses of the PHQ-9. Psychol. Med. 50, 2385–2396.
958	https://doi.org/10.1017/S0033291719002526
959	Tozzi, L., Zhang, X., Pines, A., Olmsted, A.M., Zhai, E.S., Anene, E.T., Chesnut, M.,
960	Holt-Gosselin, B., Chang, S., Stetz, P.C., Ramirez, C.A., Hack, L.M.,
961	Korgaonkar, M.S., Wintermark, M., Gotlib, I.H., Ma, J., Williams, L.M., 2024.
962	Personalized brain circuit scores identify clinically distinct biotypes in
963	depression and anxiety. Nat. Med. 30, 2076–2087.
964	https://doi.org/10.1038/s41591-024-03057-9

965	Winter, N.R., Blanke, J., Leenings, R., Ernsting, J., Fisch, L., Sarink, K., Barkhau, C.,
966	Emden, D., Thiel, K., Flinkenflügel, K., Winter, A., Goltermann, J., Meinert, S.,
967	Dohm, K., Repple, J., Gruber, M., Leehr, E.J., Opel, N., Grotegerd, D.,
968	Redlich, R., Nitsch, R., Bauer, J., Heindel, W., Gross, J., Risse, B., Andlauer,
969	T.F.M., Forstner, A.J., Nöthen, M.M., Rietschel, M., Hofmann, S.G., Pfarr, J
970	K., Teutenberg, L., Usemann, P., Thomas-Odenthal, F., Wroblewski, A.,
971	Brosch, K., Stein, F., Jansen, A., Jamalabadi, H., Alexander, N., Straube, B.,
972	Nenadic, I., Kircher, T., Dannlowski, U., Hahn, T., 2024, A Systematic
973	Evaluation of Machine Learning-Based Biomarkers for Major Depressive
974	Disorder, JAMA Psychiatry e235083.
975	https://doi.org/10.1001/iamapsvchiatry.2023.5083
976	Wurbel, MA., McIntire, M.G., Dwyer, P., Fiebiger, E., 2011, CCL25/CCR9
977	interactions regulate large intestinal inflammation in a murine model of acute
978	colitis. PloS One 6. e16442. https://doi.org/10.1371/journal.pone.0016442
979	Xie, Y., Choi, T., Al-Alv, Z., 2025, Mapping the effectiveness and risks of GLP-1
980	receptor agonists. Nat. Med. 1–12. https://doi.org/10.1038/s41591-024-03412-
981	W
982	Zelber-Sagi, S., Toker, S., Armon, G., Melamed, S., Berliner, S., Shapira, I., Halpern,
983	Z., Santo, E., Shibolet, O., 2013. Elevated alanine aminotransferase
984	independently predicts new onset of depression in employees undergoing
985	health screening examinations. Psychol. Med. 43, 2603–2613.
986	https://doi.org/10.1017/S0033291713000500
987	Zhang, L., Hu, XZ., Li, X., Chen, Z., Benedek, D.M., Fullerton, C.S., Wynn, G.,
988	Biomarker team, Ursano, R.J., 2020. Potential chemokine biomarkers
989	associated with PTSD onset, risk and resilience as well as stress responses
990	in US military service members. Transl. Psychiatry 10, 31.
991	https://doi.org/10.1038/s41398-020-0693-1
992	Zhang, Z., Robinson, L., Whelan, R., Jollans, L., Wang, Z., Nees, F., Chu, C.,
993	Bobou, M., Du, D., Cristea, I., Banaschewski, T., Barker, G.J., Bokde, A.L.W.,
994	Grigis, A., Garavan, H., Heinz, A., Brühl, R., Martinot, JL., Martinot, ML.P.,
995	Artiges, E., Orfanos, D.P., Poustka, L., Hohmann, S., Millenet, S., Fröhner,
996	J.H., Smolka, M.N., Vaidya, N., Walter, H., Winterer, J., Broulidakis, M.J., van
997	Noort, B.M., Stringaris, A., Penttilä, J., Grimmer, Y., Insensee, C., Becker, A.,
998	Zhang, Y., King, S., Sinclair, J., Schumann, G., Schmidt, U., Desrivières, S.,
999	2024. Machine learning models for diagnosis and risk prediction in eating
1000	disorders, depression, and alcohol use disorder. J. Affect. Disord. S0165-
1001	0327(24)02041-X. https://doi.org/10.1016/j.jad.2024.12.053
1002	